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 Abstract 
 Gap junctional intercellular channels allow the cells to communicate with each other. A 
breach in gap junctional intercellular communication (GJIC) affects cell growth and 
proliferation. In addition, many neoplastic cells exhibit a decrease in GJIC. Many factors that 
decrease GJIC have been shown to potentiate cancer formation. 2,3,7,8 tetrachlorodibenzo-p-
dioxin (TCDD), an environmental pollutant, is a carcinogen; however, its mechanism of 
carcinogenicity is unclear. Therefore, we examined the effect of TCDD on GJIC in MCF-7, a 
human breast cell line and normal mammary epithelial cells (HMEC). TCDD showed a decrease 
in GJIC in MCF-7 cells caused by increased phosphorylation of gap junctional protein, Cx43. 
PKCα-mediated phosphorylation of Cx43 was confirmed by inhibitor studies using calphostin C. 
Interestingly, TCDD affected GJIC in HMEC through a novel pathway involving redistribution 
of Cx43 to the perinuclear membrane. Our studies suggest that TCDD causes decrease in GJIC 
which could potentially lead to cancer. This also indicates that if GJIC is restored it could 
decrease cell growth and proliferation. Therefore, we investigated the role of substituted 
quinolines (PQ1), shown to bind with gap junctional proteins by computational docking. The 
results showed that indeed PQ1 significantly increases GJIC and exerts anti-tumor effect in 
human breast cancer cells compared to control without treatment or HMEC. We found an 
increase in GJIC, growth attenutation and increased apoptosis in T47D human breast cancer cell 
line. Our studies suggest that PQ1 is a novel gap junctional activator causing a decrease in tumor 
growth. Since PQ1 alone is effective in decreasing tumor growth in breast tumors, we proposed 
to test its efficacy with the current drug of choice for breast cancer, tamoxifen. The 
combinational treatment of tamoxifen and PQ1 showed a significant decrease in cell viability, 
increase in BAX (Bcl2-associated X), and, increase in caspase 3 activation compared to 
individual treatments. Hence, combinational treatment of PQ1 and tamoxifen can potentiate 
decrease in tumor growth. In conclusion, downregulation of gap junctions can potentiate tumor 
growth while restoration of GJIC can induce apoptosis and decrease tumor growth. 
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Abstract 
Gap junctional intercellular channels allow the cells to communicate with each other. A 
breach in gap junctional intercellular communication (GJIC) affects cell growth and 
proliferation. In addition, many neoplastic cells exhibit a decrease in GJIC. Many factors that 
decrease GJIC have been shown to potentiate cancer formation. 2,3,7,8 tetrachlorodibenzo-p-
dioxin (TCDD), an environmental pollutant, is a carcinogen; however, its mechanism of 
carcinogenicity is unclear. Therefore, we examined the effect of TCDD on GJIC in MCF-7, a 
human breast cell line and normal mammary epithelial cells (HMEC). TCDD showed a decrease 
in GJIC in MCF-7 cells caused by increased phosphorylation of gap junctional protein, Cx43. 
PKCα-mediated phosphorylation of Cx43 was confirmed by inhibitor studies using calphostin C. 
Interestingly, TCDD affected GJIC in HMEC through a novel pathway involving redistribution 
of Cx43 to the perinuclear membrane. Our studies suggest that TCDD causes decrease in GJIC 
which could potentially lead to cancer. This also indicates that if GJIC is restored it could 
decrease cell growth and proliferation. Therefore, we investigated the role of substituted 
quinolines (PQ1), shown to bind with gap junctional proteins by computational docking. The 
results showed that indeed PQ1 significantly increases GJIC and exerts anti-tumor effect in 
human breast cancer cells compared to control without treatment or HMEC. We found an 
increase in GJIC, growth attenuation and increased apoptosis in T47D human breast cancer cell 
line. Our studies suggest that PQ1 is a novel gap junctional activator causing a decrease in tumor 
growth. Since PQ1 alone is effective in decreasing tumor growth in breast tumors, we proposed 
to test its efficacy with the current drug of choice for breast cancer, tamoxifen. The 
combinational treatment of tamoxifen and PQ1 showed a significant decrease in cell viability, 
increase in BAX (Bcl2-associated X), and, increase in caspase 3 activation compared to 
individual treatments. Hence, combinational treatment of PQ1 and tamoxifen can potentiate 
decrease in tumor growth. In conclusion, downregulation of gap junctions can potentiate tumor 
growth while restoration of GJIC can induce apoptosis and decrease tumor growth. 
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Chapter 1 -  Review of Literature 
1.1.1 Introduction 
Human body is a complex network of cells forming tissues/organs and performing 
specific functions desired at a specific time. The coordinated movements in the body are a 
balancing act to achieve homeostasis. In a multi-cellular organism, homeostasis is 
mechanistically governed by three major communication processes – extracellular-
communication via hormones, growth factors, neurotransmitters and cytokines which trigger 
intracellular-communication via alterations in second messages (e.g., Ca2+, diacylgycerol, pH, 
ceramides, nitric oxide, c-AMP, reactive oxygen species) and activated signal transduction 
systems to modulate intercellular-communication governed by gap junction channels (Figure 
1.1). Cell adhesion and cell-matrix interactions are considered a subclass of intercellular 
communication molecules (Trosko and Ruch, 1998).  
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Figure 1.1  Scheme of the postulated link between extracellular communication and gap 
junctional intercellular communication via various intracellular signal transducing 
mechanisms (second message) mechanisms.  
Diagram illustrates how exogenous nongenotoxic agents can either interfere with, or mimic, 
endogenous extracellular signals. TPA= 12-O-tetradecanoyl-phorbol-13-acetate, DG= 
Diacylglycerol, DDT= Dichlorodiphenyltrichloroethane, P3= Phosphate, c-AMP= Cyclic- 
adenosine monophosphate. 
 
All of these communication processes in a multicellular organism are intimately 
interconnected to maintain its normal development and health. In effect, these communication 
processes must control a cell’s ability to proliferate, differentiate, apoptose and respond 
adaptively. Disruption of any one of these three forms of communication could lead to increased 
or decreased proliferation, abnormal differentiation, increased or decreased apoptosis and 
abnormal adaptive responses of differentiated cells. 
 
1.2 Intercellular communication 
Intercellular communication is governed by linking cells together via intercellular 
junctions (tight, desmosomes, adherens and gap junctions). These junctions are mostly present in 
epithelial cells. Desmosomes and adherens both belong to one class of junctions called anchoring 
junctions.  
 
1.2.1 Tight Junctions  
Cells such as epithelial adhere tightly to each other via junctions present on the cell 
membranes forming a tight seal to provide compartmentalization in the body. Tight junctions are 
one type of specialized intercellular junctional complex which provides a selectively permeable 
barrier to diffusion through intercellular space (Figure 1.2). These junctions tightly regulate the 
diffusion of proteins and macromolecules between the apical and the basolateral surface of the 
cell. Therefore, tight junctions regulate cell polarity, proliferation, and differentiation. The 
junctions consist of transmembrane proteins that mediate direct contact between cells, peripheral 
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membrane proteins that anchor transmembrane proteins to the cytoplasmic proteins (Shin et al., 
2006). The three major transmembrane proteins are occludins, claudins and junctional adhesion 
molecules. Transmembrane proteins associate with peripheral membrane proteins such as zonula 
occludens which anchor to the cytoplasmic proteins such as actin. Tight junctions are mostly 
impermeable to macromolecules but allowing the passage of small molecules such as inorganic 
ions, Ca2+, Na+. However, the permeability to various small molecules varies greatly in different 
tissues. Tight junctions in the epithelium lining the small intestine, for example, are 10,000 times 
more permeable to inorganic ions, such as Na+, than the tight junctions in the epithelium lining 
the urinary bladder. These differences reflect differences in tight junction proteins that form the 
junctions (Alberts, 2002). 
 
A.                                                     B.                                 
 
 
Figure 1.2  Tight junctions. 
A) Tight junctions do not have space in between them thereby allowing selective permeability. 
B) An electron micrograph of tight junctions in T47D human breast cancer cells. 
 
1.2.2 Desmosomes 
Desmosomes are buttonlike junctional complexes which join cell adhesion proteins such 
as cadherins with the intracellular intermediate filaments. Inside the cell, they serve as anchoring 
sites for ropelike intermediate filaments, which form a structural framework of great tensile 
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strength. The particular type of intermediate filaments attached to the desmosomes depends on 
the cell type such as keratin filaments in most epithelial cells and desmin filaments in heart 
muscle cells. The junction has a dense cytoplasmic plaque composed of a complex of 
intracellular anchor proteins (plakoglobin and desmoplakin) that are responsible for connecting 
the cytoskeleton to the transmembrane adhesion proteins (desmoglein and desmocollin) (Alberts, 
2002). Figure 1.3A is a diagram showing the different proteins involved in desmosomes and 
Figure 1.3B shows an electron micrograph of desmosomes in the heart tissue of a mouse.   
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Figure 1.3  Desmosomes. 
A) Diagram showing different proteins involved in forming a desmosome. B) An electron 
micrograph of desmosomes in the heart tissue of a mouse. The main function of desmosomes is 
to hold the plasma membrane of two cells together. 
 
1.2.3 Adherens Junctions 
 Adherens junction is a type of anchoring junctions which anchor cells together through 
their cytoplasmic actin filaments. It occurs in various forms such as small punctate or streak-like 
attachments. But the prototypical examples of adherens junctions occur in epithelia, where they 
often form a continuous adhesion belt (or zonula adherens) just below the tight junctions, 
encircling each of the interacting cells in the sheet. Figure 1.4A shows a diagrammatic view of 
adherens junctions while Figure 1.4B is an electron micrograph of adherens junctions in a heart 
muscle of a mouse. The transmembrane proteins are composed of cadherins, E-cadherins, N-
cadherins, and integrins.  Cadherins, E-cadherins, and N-cadherins are proteins that anchor to 
other cells while integrins function as anchor to extracellular matrix. It plays an important role in 
the morphogenesis of organs, mediating the folding of epithelial cell sheets into tubes and other 
related structures.  
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Figure 1.4  Adherens junctions. 
A) Diagram showing the proteins involved in forming adherens junctions. B) An electron 
micrograph showing adherens junctions in the heart tissue of a mouse. 
 
1.2.4 Gap junctions  
 A gap junction is the only intercellular communication which provides a direct 
connection between the cytoplasmic spaces of the two neighboring cells. It forms a bridge 
between the cells allowing the passage of molecules from one cell to another. Gap junctions play 
an important role in cell growth, differentiation and maintaining homeostasis. My dissertation 
will focus on gap junctions and their significance in our body. 
 
1.3 Gap junctions 
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Gap junctions are transmembrane hydrophilic channels allowing the passage of 
molecules less than 1200 Daltons (Da) between the cells through the intracytoplasmic space.  
 
 
                  
Figure 1.5  Structure of a gap junction.  
The figure shows that two connexons (in blue and red) on different plasma cell membrane 
appose together to form a channel of 1.5 nm diameter. Each connexon is composed of six 
connexin proteins. 
 
Gap junctions are formed when one connexon (a hemichannel consisting of hexameric 
subunits of connexins) of one cell docks with a connexon of an adjacent cell as shown in Figure 
1.5 (Steel, 1998). The passage of small molecules through gap junctions suggests that the 
maximal functional pore size for the channel is about 1.5 nm in diameter in mammalian cells 
(Oyamada, 1998). Small molecules such as cAMP, inositol triphosphate, glucose, and calcium 
ions can pass while large molecules such as proteins or complex sugars cannot pass through the 
gap junctions (Figure 1.6) (Alexander and Goldberg, 2003). Gap junctions are the only 
specialization of the cell membranes which allows the communication between the adjacent cells 
(Dagli and Hernandez-Blazquez, 2007).  
Several hundreds of gap junction channels in the contact regions of the adjacent cells 
forms an aggregation known as gap junctional plaques (Werner, 1998a). Each gap junctional 
plaque consists of a large number of connexons. Bukauskas et al. showed that the formation of 
gap junctional plaques is a prerequisite for the functional gap junctions (Bukauskas et al., 2000). 
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They found that coupling was absent in small plaques but present in larger plaques. Extensive 
analysis of the exchange of a range of small fluorescent dyes injected into cells has become a 
popular technique to establish whether cells are functionally coupled by gap junctions. These 
studies have uncovered charge and size discrimination of the channel within a 0.2 ± 1.0 KDa 
envelope, mainly in HeLa cells expressing recombinant gap junction channels constructed of 
various connexin isoforms (Elfgang et al., 1995; Cao et al., 1998; Nicholson et al., 2000). 
 
1.3.1 Structure of connexin  
Intercellular junctions between the cells have been given different names as nexus, 
macula communicans, and gap junction. But the term gap junctions by Revel and Karnovsky got 
the scientific acceptance despite the contradiction between the function and the morphological 
characteristics it denotes (Revel and Karnovsky, 1967). The name could be justified by the 
revelation of the gap observed between the adjacent plasma membranes by electron microscopy 
(Ogawa, 1993). 
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Figure 1.6  Schematic diagram illustrating the selective trans-junctional properties of gap 
junctions in intercellular communication. 
Gap junction channels can be permeable to – (A) small molecules (B) small molecules with 
elongated shapes or (C) combinations of both molecular shapes. It is also important to note that 
the charge of the trans-junctional molecule also governs permeability characteristics. Gap 
junctions are typically not permeable to molecules exceeding 1 KDa (purple) (Laird, 2006). 
 
In 1967, Revel and Karnovsky identified that the cross-sectional profile of gap junctions 
is displayed as two plasma membranes separated by an intercellular gap, observed by infiltration 
of lanthanum or horseradish peroxidase between the gap (Revel and Karnovsky, 1967). Freeze- 
fracture replication and negative staining further showed that gap junctions are patchy arrays of 
closely packed membrane channels in a hexagonal or polygonal matrix forms. An exact analysis 
of the structure of gap junction channels was identified through in vitro isolation from the liver 
by sucrose gradient centrifugation and subsequent detergent treatment (Dermietzel et al., 1990). 
X-ray diffraction experiments performed on the isolated gap junctions suggest that the portion of 
gap junction channel contributed by each connexon is composed of six subunits, connexins (Cx), 
together possessing a hexameric structure (Goodenough, 1976). The amino acids derived from 
the cloned cDNAs helped in predicting the structure of connexins (Hertzberg, 2000). Each 
connexin consists of four hydrophobic transmembranes and two extracellular and three 
cytoplasmic loops (Figure 1.7). The N and C termini face the cytoplasmic side of the cell while 
the extracellular side contains two extracelluar loops (Sosinsky, 1996). The most conserved 
regions in the connexin are localized to the extracellular loops followed by less conserved region 
of four membrane-spanning domains and carboxy-terminus, amino-terminus and cytoplasmic 
loops exhibit variable region. Connexins differ markedly from each other in sequence and length 
mainly based on their carboxy termini and the cytoplasmic loop (Hertzberg, 2000). 
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Figure 1.7  Connexin structure.  
The cylinders represent transmembrane domains (M1-M4). The loops between the first and 
second, as well as the third and fourth, transmembrane domains are predicted to be extracellular 
(E1 and E2, respectively). The carboxy-terminus has many phosphorylation sites (Korkiamaki, 
2002). 
 
1.3.2 Nomenclature of connexins  
The diverse and ubiquitous distribution of gap junctions is possible due to the fact that 
the connexin family consists of 20 members in the mouse and 21 members in humans (Laird, 
2006). However, connexins are highly related (50-80%) to each other, differing in the 
cytoplasmic portion sequences (Goodenough et al., 1996). They have molecular masses between 
25 and 62 KDa; thus the size of each connexin is used for the nomenclature of the proteins 
(Evans et al., 2006). In some instances, a prefix including the species name is added while 
describing the protein. For example, the most abundant and prominent connexin in rat heart is a 
43,036 Da protein, hence called rat Cx43. The finding that two or more connexins have the same 
molecular mass has lead to a decimal point to distinguish them, for example mouse Cx30.3 or 
mouse Cx31.1 (Saez et al., 2003). Another nomenclature is also used to describe connexins also; 
however, less commonly used. This nomenclature is based on the degree of relatedness of 
different connexins. The analysis for the sequence relation and phylogeny of connexin 
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polypeptide sequences categorize connexins into two groups: α and, β. The α group includes 
Cx33, Cx37, Cx38, Cx40, Cx43, Cx45, Cx46, Cx50, and Cx56 while β comprises Cx26, Cx30, 
Cx30.3, Cx31.1, and Cx32 (Kumar and Gilula, 1992; Hertzberg, 2000).  
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Figure 1.8  (A) Immunofluorescence of Cx46 in a mouse heart tissue. (B) DAB staining of 
Cx43 in a mouse heart tissue (C) Electron Microscopic view of gap junctions in a mouse 
heart tissue. (D) Immunogold labeling of Cx43 in a mouse heart tissue (70,000 X). 
 
The function of gap junctions in cell is of utmost importance because of their presence in 
nearly every mammalian cell type. Gap junctions appear as plaques of varying size, as these unit 
channels accrete laterally in the plasma membrane and have been studied by electron microscopy 
of immunogold labelled freeze-fracture replicas (Rash and Yasumura, 1999), by 
immunocytochemistry (Dupont et al., 2001) and by fluorescently tagged connexins (Bukauskas 
et al., 2000; Falk, 2000; Rutz and Hulser, 2001). Figure 1.8 shows the expression of Cx46 and 
Cx43 in mouse heart tissue by different methods.  
 
1.3.3 Tissue specific expression of connexins  
Gap junctions are found in very primitive invertebrates like hydra, jellyfish and similar 
structures known as plasmodesmata are found in plants (Trosko and Ruch, 1998). In vertebrates, 
gap junctions are found in all cell types except red blood cells, platelets, spermatozoa, and 
skeletal muscle fibres. Nevertheless, gap junctions are present in the progenitors of these cell 
types (Rosendaal et al., 1994; Constantin et al., 1997; Proulx et al., 1997; Mok et al., 1999). 
Moreover, it has been observed that different connexins are present in different tissues. Most 
cells express two or more connexins (Saez et al., 2003). Presence of different connexins in 
different tissues suggests specific roles of different connexins. For example, keratinocytes 
express at least Cx26, Cx30, Cx30.3, Cx31, Cx31.1, and Cx43. Cardiomyocytes express Cx43, 
Cx40, and Cx45 and hepatocytes express Cx26 and Cx32 (Table 1.1) (Laird, 2006). Collectively, 
co-expression of multiple connexin family members within the same cell type allows for possible 
compensatory mechanisms to overcome the loss or mutation of one connexin family member 
(Laird, 2006). Different connexins do show selective permeability. Cx26 has been shown to form 
smaller pore size gap junction channels than Cx32. Cx43 gap junctions were shown to readily 
pass lucifer yellow dye than Cx45 gap junctions (Steinberg et al., 1994). Cx43 appears to be the 
most predominant connexin in terms of the number of tissues expressing it and the concentration 
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present in tissues (Hertzberg, 2000). Cx43 mRNA is particularly abundant in heart, relatively 
lower in mammary gland, ovary, lens epithelium, kidney, and uterus (Hertzberg, 2000).  
 
1.3.4 Factors regulating gap junctions  
Gap junctional intercellular communication (GJIC) is regulated at many levels, ranging 
from gene regulation, gap junction assembly formation, gating at the plasma membrane and gap 
junction degradation. Two major kinetic courses of GJIC control have been discussed − fast 
control (millisecond range) and the long term control (hour range).  
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Table 1.1  Representative tissues and cell types where mouse connexin family members are found. 
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The half life of connexins is very short ranging from 1.5-2 hours. The fast control is 
referred to as gating which is affected by many factors like H+, Ca2+, pH, and phosphorylation. 
Among these actions, phosphorylation at the carboxy termini has been widely studied. 
Phosphorylation of the N-terminal region of connexins that is cytoplasmically located is not 
reported (Lampe and Lau, 2000). Most connexin family members are phosphoproteins, except 
Cx26. Several kinases are known to target connexin proteins, including MAPK (Mitogen-
activated protein kinase), PKC (Protein kinase C), PKA (Protein kinase A), and CK1 (Casein 
kinase 1). Connexin phosphorylation has been implicated in the regulation of intercellular 
communication through a number of mechanisms, including connexin biosynthesis, trafficking, 
assembly, membrane insertion, channel gating, internalization and degradation. Cx43 has been 
the most studied connexin in terms of modification by many kinases (Saez et al., 2003). The 
different phosphorylation sites identified on the carboxyl terminus are: Ser-368 and Ser-372 
phosphorylated by PKC; and Ser-255, Ser-279, and Ser-282 phosphorylated by MAPK (Figure 
1.9). Many studies describe the changes in the state of phosphorylation of Cx43 by PKC-
dependent pathways. Ser-368 of Cx43 appears to be an important site since mutation of Ser-368 
partially prevents the cellular uncoupling induced by phosphorylation caused by PKC in the 
presence of phorbol ester (TPA) (Liu and Johnson, 1999; Lampe et al., 2000). The closure of gap 
junctions is either induced by cell trauma (sudden drop in pH, increase in Ca2+ level or decrease 
in the voltage) or physiological regulators like phosphorylation (Werner, 1998b).  
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Figure 1.9  Cx43 binding proteins. 
Protein kinases known to phosphorylate Cx43 are shown along the top of a schematic diagram of 
gap junction plaque. A number of scaffolding proteins and proteins of unknown function that 
have been shown to bind directly or indirectly to Cx43 are shown along the bottom of the gap 
junction plaque. It is important to note that it is not necessarily expected that all proteins shown 
here bind to Cx43 while it is a resident of the gap junction plaque. MAPK; CIP85, Cx43-
interacting protein of 85 KDa (Laird, 2006). 
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1.3.5 Functional assays to measure gap junctions 
Studies to assess the functionality of gap junctions can be divided into two groups: 
A) Measurement of dye transfer 
B) Measurement of metabolic cooperation and electrical conductance 
 
A) Measurement of dye transfer  
 
Dye transfer involves measuring the movement of nontoxic dyes from one cell to another. 
Molecules should be small enough in the range of < 1 KDa to cross through the gap junctions. 
The techniques to measure dye transfer are: 
 
Microinjection: Microinjection of non-permeable, nontoxic tracers has been the first technique 
used to identify cell-cell communication (Abbaci et al., 2008). Individual cells are injected with 
a fluorescent dye in a micropipette having a diameter of 0.2 µ, using appropriate pressure. Since 
the onset and duration of the tracer is well controlled, kinetic studies can be performed showing 
the rate of transfer of the tracer from one cell to another (Bruzzone, 1999). Lucifer yellow is the 
most widely used fluorescent dye for this technique, after replacing fluoroscein as it was shown 
to cross nonjunctional membranes.  
Advantages: It allows selective loading of tracer molecule which permits correlation of 
the morphological and functional data from an individual cell. The onset and the duration of the 
tracer injection can be accurately controlled, allowing the measurement of dye transfer from one 
cell to another.  
Limitations: It requires a special instrument to inject the tracer in an individual cell 
without damaging the cell. Also, this technique is not useful if the tracer is going to be injected in 
many cells at one time. Results obtained by this method vary with the investigator’s experience 
in impaling cells without causing too much damage and discriminating stained from unstained 
(autofluorescent) cells. 
 
Scrape Load/Dye Transfer (SL/DT): Scrape load dye transfer is a very simple technique in 
which monolayers of adherent cells are scraped in the presence of a membrane-permeable dye, 
which becomes incorporated into the cells at the line of cut by mechanical perturbation of the 
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cell membrane. The distance at which the fluorescent dye diffuses during a certain period away 
from the scrape line is indicative of GJIC. Lucifer yellow (MW=443 Da), diameter of 0.5-0.7 nm 
is the most commonly used dye for SL/DT. Rhodamine dextran with a molecular weight of 
10,000 Da is used as a control. 
Advantages: This technique does not require any special equipment. It allows the 
measurement of GJIC in a large number of cells. It is a fast and a simple technique, relatively 
short period from the time of preparation to obtaining the results. 
Limitations: The technique is hardly adequate to investigate small cells or cell assemblies 
(such as pairs), as well as low density cultures. It is also complicated when the extent of 
junctional coupling is small or when selected cells have to be individually screened for coupling. 
This technique is not well suited to three-dimensional systems because this invasive method may 
introduce uncertainities in quantifying dye transfer rates due to variations in cell-staining 
intensity after scrape loading (Dakin et al., 2005).  
 
Electroporation: This technique was introduced by Raptis et al. proposing the introduction of a 
non-permeable dye into the adherent cells on a partly conductive slide (Raptis et al., 1994). Cells 
are grown on a glass slide, half of which is coated with electrically conductive, optically 
transparent, indium-tin oxide. An electric current which opens the pores is applied on the 
conductive side of the slide in the presence of Lucifer yellow. The transfer of the dye to the cells 
on the non-conductive side is measured. 
Advantages: The gap junctional permeable dye, Lucifer yellow, can enter into large 
number of cells with minimal disturbance to the cellular metabolism. It is a satisfactory method 
for loading a narrow longitudinal strip of cells for subsequent studies on the temporal and spatial 
spread of fluorescent dyes via gap junctions. 
Limitations: This technique cannot be used for non-adherent cells. If cells are grown to 
high confluency, chances of cells getting detached from the slide when electrode is removed are 
higher.  
 
Gap-FRAP (Fluorescence recovery after photobleaching): Fluorescent molecules in a small 
region of the cell are irreversibly photobleached using a high-powered laser beam, and 
subsequent movement of surrounding nonbleached fluorescent molecules into the photobleached 
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area is recorded at low power laser over time (Lippincott-Schwartz et al., 2001). FRAP data 
requires that the bleach event is much shorter than the recovery time and preferably as short as 
possible (Lippincott-Schwartz et al., 2003).  
 Advantages: It is a non-invasive technique compared to microinjection and SL/DT. 
Therefore, the risk of cell injury is minimal to negligible. It enables to quantify and compare 
GJIC capacity between characterized cell types. Kinetic curves can be established to precisely 
measure the functionality of GJIC (Abbaci et al., 2008).  
 Limitations: The gap-FRAP technique requires a laser beam coupled with an 
epifluorescence microscope or, commonly, a confocal laser-scanning microscope, all of which 
are sophisticated and expensive instruments. To avoid photochemical and/or thermal cell injury, 
a highly sensitive light detector should be used; the minimization of illumination thereby reduces 
the amount of energy absorbed by the specimen (Abbaci et al., 2008). 
 
Preload assay or Parachute assay: This method consists of preloading cells with a gap 
junctional-permeable dye, such as calcein-AM (green dye), and then letting suspended loaded 
and unloaded cells form a confluent monolayer together. As suspended loaded cells are added to 
the monolayer, the parachute assay requires formation of gap junction channels in order to 
measure subsequent intercellular communication. Depending on the cells and the technique used, 
the loaded cells/donor cells form gap junctions in 15 min-3 hr with the recipient cells (Goldberg 
et al., 1995; Ziambaras et al., 1998). To distinguish recipient cells from the donor cells after the 
passage of calcein-AM, the recipient cells can be labeled with other non-gap junctional dye 
(Vybrant-DiD, red dye). Therefore, the recipient cells will be having both green and red dye. 
 Advantages: The parachute technique is a non-invasive method since the integrity of the 
cells is maintained. Flow cytometry enables simultaneous analysis of a large number of cells (at 
least 104 cells) (Jongen et al., 1991). It ensures objectivity and statistically reliable data. 
 Limitations: This method is not applicable to the vast majority of adherent cell types in 
culture (Meda, 2001). By flow cytometry, nonspecific dye transfer of calcein has been observed 
in many studies (Koval et al., 1995; Fonseca et al., 2004). The preloading assay is also a time-
consuming method that is influenced by the section studied (cells in different areas of the dish 
can behave differently), the resolution, and sensitivity of the microscope equipment (Czyz et al., 
2000). 
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B) Measurement of metabolic cooperation and electrical conductance 
 
Many molecules, exchanging in vivo by coupled cells, have various dimensions and 
charges and hence may be restricted or facilitated in their passage through gap junction channels, 
depending on the type of connexins (Koval et al., 1995; Meda, 2001). Some investigators have 
examined the transfer of endogenous compounds by metabolic cooperation (Larson and 
Sheridan, 1985; Saez et al., 1989; Charles et al., 1992). 
 
Metabolic cooperation by radiolabel nucleotides: A population of donor cells is incubated in 
the presence of an excess of a radiolabeled precursor (typically uridine) and then co-cultured 
with unlabeled recipient cells. Under such conditions, quantitative autoradiography enables 
evaluation of the transfer of the resulting metabolites from loaded to unloaded cells as a function 
of time. In this type of experiment, coupling is demonstrated by the autoradiographic labeling of 
the cytoplasm of recipient cells due to the incorporation in their ribonucleic acid of radiolabeled 
nucleotide synthesized within donor cells and transferred across gap junction channels (Meda, 
2001).  
Advantages: Direct transfer of radioactive nucleotides allows the evaluation of the 
permeability of gap junction channels in a highly sensitive way. Contrary to the synthetic dyes, 
radioactive nucleotides can better represent the transfer of biological molecules across the cell 
membrane.  
Limitations: The measurement of labeled nucleotides and nucleic acids from a damaged 
donor cell to the recipient cell could be possible. Safety must be rigorously practiced especially 
dealing with aerosol particles produced during cell sorting procedures, incubation and metabolic 
labeling. 
 
Measuring electrical conductance by dual patch clamp technique: The dual patch clamp 
technique is a powerful method for quantitative determination of junctional conductance (Van 
Rijen, 2001). A freshly made glass pipette with a tip diameter of only a few µm is pressed gently 
on the cell membrane to form a gigaseal. The membrane breaks when the suction is applied 
leading to the mixing of the cytoplasm and pipette solution. Currently, the most widely used 
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dual-voltage clamp method is the double whole-cell voltage clamp with one suction pipette on 
each cell of a cell pair (Wilders and Jongsma, 1992). The method consists of separately 
controlling the membrane potential of each cell and measuring the corresponding currents.  
Advantages: This method is the most sensitive technique to detect functional gap 
junctions: a single gap junction channel can be recorded, in contrast to dye transfer. This is the 
most common method to assay the electrical properties of gap junctions. The technique has been 
used to study ionic permeability and selectivity of gap junction channels. Measurements of 
electrical conductance between cells can be used to determine the number of gap junction 
channels that are open within a given period of time (Alexander and Goldberg, 2003).  
Limitations: Analysis of electrical conductance is a slow, labor-intensive, and expensive 
technique. Obtaining reliable and reproducible measurements of junctional ionic permeability 
can be difficult since the integrity of coupled cells can be disrupted due to the change of internal 
ionic environment.  
 
1.4 Breast Cancer 
 
1.4.1 Breast cancer and factors affecting breast cancer  
More than 80-95% cases of breast cancer are ductal whereas 8% cases are lobular. Both 
these types of breast cancers are invasive. Invasive or infiltrating breast cancer also includes 
another type of breast cancer – inflammatory breast cancer. For 2007, the estimates by American 
Cancer Society are that 178,480 women in the United States will be diagnosed of invasive breast 
cancer while an additional 62,030 women will be diagnosed with ductal carcinoma in situ 
(DCIS). For 2008, the estimated US breast cancer cases by American Cancer Society was 
179,920 while deaths caused by breast cancer was 40,729. 
The three most significant risk factors for breast cancer are – being a woman (male breast 
cancer occurs at 1% the rate of female breast cancers), age and hereditary susceptibility. 
Hormonal stimulation (estrogen and progesterone) of the breast tissue co-relates with being a 
woman, long exposure to exogenous carcinogens co-relates with living, and mutations in the 
genes corresponds to the hereditary susceptibility. These three risk factors are integrated in life 
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process that cannot be controlled. The other risk factors include – early menarche, late 
menopause, nulliparity, postmenopausal obesity, environmental pollutants and hormone 
replacement therapy. Protective factors are the factors which help in reducing the risk of getting 
breast cancer. These include – decreasing the lifetime exposure to estrogen (prolonged lactation, 
ovariectomy, and exercise), maintaining a healthy lifestyle by avoiding intake of alcohol, eating 
a low-fat diet. Hereditary factors include mutations in the two breast cancer genes – BRCA1 and 
BRCA2, accounting for less than 10% of the breast cancer cases (Gray, 2009). Women with an 
inherited mutation in BRCA1 and BRCA2 have 60-82% chance in getting breast cancer in the 
lifetime (King et al., 2003). This suggests that even beyond the identified mutations, there are 
other factors like lifestyle and environment which affect the development of breast cancer. For 
example, female BRCA1 carriers born after 1940 have nearly twice as much breast cancer by 
ages 40 and 50 as those born earlier (King et al., 2003). In a large twin study conducted, 
inherited genes were found to contribute 27%, shared environmental factors 6%, and non-shared 
environmental factors 67% of the breast cancer risk (Lichtenstein et al., 2000).  
Hormonal factors accounts for a quarter of breast cancer cases (Seidman et al., 1982). 
Clearly, being a woman as one of the risk factors points to the steroid hormones circulating in a 
female body. Estrogen and progesterone are the two major steroid hormones in a female 
endocrine system. These hormones are required for the normal development of the female body; 
however, the action of estrogen in breast tissue is quite varied. The most studied mode of action 
is mediated through the interaction with the estrogen receptor α (ERα). ERα is a nuclear receptor 
localized inside the nucleus of certain type of cells (endometrial, breast). Upon binding of 
estradiol or estradiol-like molecules, there is a change in the structure of ERα leading to either 
homo or hetero- dimerization of the receptor. The ER-complex binds to estrogen-responsive 
elements in the regions of DNA which regulate the expression of a range of proteins that 
collectively promote the growth of mammary epithelium. Among the downstream mediators of 
estrogen action are epidermal growth factor (EGF), its ligand amphiregulin, transforming growth 
factor α and β (TGF-α and β), platelet derived growth factor (PDGF), and the insulin-like growth 
factors (IGF-I and IGF-II).  
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1.4.2 Role of environmental pollutants in breast cancer 
One of the risk factors for breast cancer is exposure to environmental chemicals with 
endocrine property. An estimated 80,000 synthetic chemicals are used today in the United States, 
and another 1,000 or more are added each year (Seidman et al., 1982). Yet complete 
toxicological screening data are available for just 7% of these chemicals and more than 90% 
have never been tested for their effects on human health (Devesa et al., 1995). Mammary gland 
is largely composed of adipose tissue; therefore, lipophilic compounds are under frequent 
investigation as these can get accumulated in the breast tissue for years (Warshawsky, 2006). A 
list of chemicals has been registered by the International Agency for Research on Cancer (IARC) 
as carcinogens and has also received ratings by regulatory agencies regarding induction of 
human breast and animal mammary tumors. Some of the chemicals included in the list are 
bisphenol A, polyaromatic hydrocarbons, tobacco smoke, dioxins, alkylphenols, metals, 
phthalates, parabens, pesticides such as dieldrin, aldrin, atrazine, benzene, polyvinyl chloride, 
1,3-butadiene, ethylene oxide and aromatic amines (Gray, 2008). Some of these chemicals are 
found in maternal blood, placental tissue, breast milk samples from pregnant women, and 
mothers who have recently given birth, indicating that maternal burdens of environmental 
contaminants are being passed on to their young during pregnancy and breastfeeding (Van der 
Ven et al., 1992; Anderson and Wolff, 2000; Chen et al., 2006; Shen et al., 2007). 
A wide variety of chemicals including plastic additives, industrial solvents, pesticides, 
herbicides, and chemical byproducts of combustion or industrial manufacturing processes, can 
mimic or alter the activities of the natural hormones, especially the estrogens. The xenoestrogens 
are members of a larger class of synthetic chemicals known as endocrine disruptors. Endocrine 
disruptors mimic or disturb the activity of a much wider group of hormones, including the 
androgens, adrenal hormones, and thyroid hormones. The term “endocrine disruptor” is used to 
reflect compounds that affect the endocrine system (Gray, 2009). Few examples of endocrine 
disruptors are dioxin and dioxin like compounds, organochlorine compounds such as DDT, 
diethylstilbesterol (DES), polychlorinated biphenyl (PCBs), and some other pesticides. Some 
chemicals, particularly pesticides and plasticizers, such as Bisphenol A are suspected endocrine 
disruptors based on animal studies (Sciences, 2007). 
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1.4.3 TCDD and cancer  
2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD, also known as dioxin) is an aryl 
hydrocarbon receptor agonist. TCDD was first listed in the Second Annual Report on 
Carcinogens as reasonably anticipated to be a human carcinogen in 1981 which later on in 2001 
was supported by both epidemiological and mechanistic studies indicating causal relationship 
between TCDD and human cancer. TCDD is very persistent in the environment, but it can be 
slowly degraded by sunlight (ATSDR, 1998; HSDB, 2003). It has a half-life of 5.8 to 11.3 years 
in humans (Olson, 1994); therefore, TCDD accumulates in human tissue at a higher rate when 
compared to most experimental animals following chronic low-dose exposure. Polychlorinated 
dibenzo-p-dioxins (CDDs), including TCDD, are inadvertently produced by paper and pulp 
bleaching, by incineration of municipal, toxic, and hospital wastes, in PCB-filled electrical 
transformer fires, in smelters, and during production of chlorophenoxy herbicides (Silkworth, 
1996; Schecter, 1997; Schecter et al., 1997). The greatest unintentional production of CDDs 
occurs from waste incineration, metal production, and fossil fuel and wood combustion 
(ATSDR, 1998). World Health Organization (WHO), National Institute for Occupational Safety 
and Health (NIOSH), and the U.S. Environmental Protection Agency (EPA) concluded that 
dioxin increases the risk for all cancers (ATSDR, 1998). However, the mechanism by which 
TCDD can promote cancer is unclear.  
 
1.4.4 TCDD and gap junctions  
The abilities to stimulate cellular proliferation and inhibit GJIC and apoptosis are thought 
to be essential properties of promoters (Koblyakov, 1998). The ability of the initial non-
metabolized polyaromatic hydrocarbon molecule to stimulate cell proliferation and to inhibit 
GJIC provides evidence to consider that polyaromatic hydrocarbon mediate the promotion stage 
in the initial form during carcinogenesis induced by this group of compounds (Sharovskaja et al., 
2004). In the present study, we examined the effect of TCDD on gap junctions in human breast 
cancer cells (MCF-7) and human mammary epithelial cells (HMEC). Our research sheds light on 
the mechanism of action of TCDD on GJIC in human breast tissue via cell model system. 
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1.5 Cancer and Gap Junctions 
 
1.5.1 Gap junction in human mammary gland  
Gap junctions are present in all cell types of vertebrates, except few dynamic cells  
(spermatozoa, red blood cells, platelets) and mature skeletal muscle fibers (Abrams et al., 2003). 
Out of the various organs, heart and mammary gland, have been studied in greater depth for gap 
junctions. Cx43 has been shown to be widely present in heart and mammary gland. The 
mammary gland undergoes growth, development and differentiation at many stages of life. 
Therefore, it requires a precise intercellular communication for its proper development and 
differentiation. One such communication is gap junction. So far, the human mammary gland has 
been shown to express only Cx43 and Cx26. The basal myoepithelial cells are consisted of Cx43 
while luminal epithelial cells express Cx26 and Cx43 (McLachlan et al., 2007). Studies have 
speculated that in the resting human mammary gland Cx43 is required to maintain myoepithelial 
differentiation and more variable Cx26 presence could have a dynamic role in luminal cell 
proliferation (Lee et al., 1992).  
 
1.5.2 Aberrant gap junctions and cancer  
Pioneering studies by Lowenstein and Kanno in 1966 suggested that cancer cells have 
decreased cellular communication than normal cell confirmed by junctional membrane resistance 
(Loewenstein, 1966). The lack of gap junctional intercellular communication in cancer could be 
due to two main reasons – the lack of expression of connexin genes or the aberrant localization 
of connexin proteins. The lack of expression of genes could be due to lack of transcription 
caused by hypermethylation of the CpG islands. The downregulation of Cx32 gene expression by 
hypermethylation of the CpG island of the Cx32 gene has been observed in human renal 
carcinoma cell line and human renal carcinomas (Yano et al., 2004). 
 
1.5.3 Gap junctions in breast tumors  
Cancer is a complex and evolving disease with the formation of defects at multiple 
genetic steps in a cell. Cancer was the first pathology associated with the defects in gap 
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junctions. In 1966, Lowenstein and Kanno associated GJIC with cell growth control 
(Loewenstein, 1966). They observed a decrease in electrical coupling in rat hepatomas compared 
to normal liver cells. A series of molecular mechanism showed that cancer phenotype is related 
to loss of coupling (Cronier et al., 2009). Since the most obvious observation in tumor cells 
phenotype is deregulated growth, the assumption of all the studies is that gap junctions are 
involved in cell growth control (Mesnil, 2002). Recently, gap junction deficiency has been 
defined from either lack of gap junctional plaques observed by ultrastructure approaches 
(electron microscopy and freeze-fracture) or by decrease in GJIC (Mesnil et al., 2005). It is a 
debatable question that how far connexins are from the primary insult and whether they play a 
key role in carcinogenesis or simply is it a secondary effect to cancer (McLachlan et al., 2007). 
 Deficiency of Cx43 gap junction can be used as an independent marker for breast tumors 
(Laird et al., 1999). Early studies showed downregulation of Cx26 and Cx43 in the primary cells 
derived from human breast tumor (Lee et al., 1992), rat mammary tumors (Laird et al., 1999), 
and breast cancer cell lines ((Laird et al., 1999; Singal et al., 2000). Since, the promoter of Cx26 
is located within a CpG island, it is speculated that the methylation of these sites could lead to 
the repression of the gene (McLachlan et al., 2007). Investigational studies by Singal et al. found 
hypermethylation of Cx26; however, inhibition of a DNA methyltransferase did not induce the 
expression of the gene (Singal et al., 2000). On the contrary, Tan et al. found that only one in 
eight breast cancer cell lines tested was hypermethylated in the Cx26 promoter region but that, in 
this case, it correlated with a complete loss of mRNA that was recovered after treatment with a 
DNA methyltransferase inhibitor (Tan et al., 2002). Furthermore, the Cx26 promoter was found 
to be methylated in >50% of patient tissue samples tested, albeit heterogeneously. These 
conflicting results suggest that Cx26 may indeed be a tumor suppressor that is inactivated by 
methylation, but this is likely not the only mechanism to downregulate expression (McLachlan et 
al., 2007). Upregulation of phosphorylated forms of Cx43 was observed in both myoepithelial 
cells and transformed luminal cells of in situ carcinomas and all cells of invasive breast 
carcinomas (Gould et al., 2005). Connexins are mostly present on the cell membrane but in some 
tumors despite an increase in connexins, they are typically retained in the intracellular 
compartments. Kanczuga-Koda et al. report that the level of Cx43 expression, which was 
cytoplasmic in 90% of the tumors, was positively correlated with advanced histological grade of 
the tumor (Kanczuga-Koda et al., 2005). 
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1.5.4 Effect of restoration of gap junctions on cancer  
Connexins were described as class II tumor suppressor because the genes encoding 
connexin protein is not mutated but the protein expression is affected (Lee et al., 1992). 
Specifically, Cx26 was first deemed as a tumor suppressor in 1991. Mehta et al. showed that the 
transfection of a gene for Cx43 protein in mouse transformed 10T1/2 cells having low GJIC 
leads to a decrease in the cell growth, reduced saturation density and focus formation 
suppression (Mehta et al., 1991). Transformed dog kidney epithelial cells after transfection with 
Cx43 showed restored GJIC, became flatter in cell morphological appearance, decreased 
expression of cell cycle-regulatory genes such as cyclin A, D1, D2, and cyclin D kinase 5 and 6 
(Chen et al., 1995). Transfection of C6 glioma cells with Cx43 (Zhu et al., 1991) and of human 
hepatoma cell line SKHep1 with Cx32 (Eghbali et al., 1991) provides preliminary evidence that 
the growth of transfectants and tumors in nude mice decreases. HUVEC endothelial cells were 
transfected with Cx37 showed increased GJIC and increase in apoptosis measured by caspase 
assay and DNA fragmentation. Many studies have also shown a decrease in cell or tumor growth 
in the presence of Cx43 despite forming GJIC (Koffler et al., 2000; Qin et al., 2002). 
Transfection of Cx26 and not Cx32 in HepG2 cells caused an increase in dye transfer, decrease 
in the saturation density and tumor growth. HepG2 cells also showed a change in the 
morphological appearance of the cells from multilayer to monolayer formation (Yano et al., 
2001). In another study, transfection of MDA-435C cell line with either hCx43 or hCx26 gene 
caused a restoration in GJIC, decrease cell growth and smaller size tumor formation in mice 
(Hirschi et al., 1996). All these studies suggest a potential role of connexin genes as tumor 
suppressors.  
 
1.5.5 Design and synthesis of quinolines  
In search of new activators that enhance GJIC, we collaborated with Dr. Duy H. Hua in 
the Department of Chemistry at Kansas State University who examined the potential interactions 
of a number of substituted quinolines (code name PQs) with the partial crystal structure of 
connexon (Makowski et al., 1977; Foote et al., 1998; Fleishman et al., 2006) using Autodock 
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computational docking software (Goodsell and Olson, 1990; Morris et al., 1996; Morris, 1998). 
Scientists in Dr. Hua’s lab observed binding of PQs to the inert pore of the hexameric 
hemichannel of gap junctions. The connexon structure was constructed by using electron 
cryomicroscopy to derive a three dimensional density map at 5.7 Å in plane and 19.8 Å vertical 
resolution, and analysis of evolutionary conservation and compensatory mutations in connexin 
evolution to identify the packing interfaces between the helices (Fleishman et al., 2006). In one 
of the minimum energy (-0.7 kcal/mol) bound structures, interactions (closed contact) between 
CF3 group of PQ1 and NH of Leu144 of connexin (2.5 Å), OCH3 group of PQ1 and CH2 of 
Phe81 of connexin (2.0 Å), and NH3 + of PQ1 and –O2CGlu146 of connexin are found. 
Consequently, they synthesized this class of quinolines and studied their GJIC and anticancer 
activities (Gakhar, 2008). Since PQ1 (one of the substituted quinolines) is predicted to have a 
high binding affinity for connexin via computational docking (Figure 1.10), we tested PQ1 and 
its synthetic precursors effect on the GJIC in T47D breast cancer cells. 
 
 
Figure 1.10  Docking of PQ1 with connexin. 
Six connexins form a connexon. The figure illustrates docking of PQ1 (pink) with the connexin 
protein. The computational docking software docks the PQ1 based on the lowest energy levels. 
The diagram hypothetically depicts one PQ1 molecule binding to the connexin protein; however, 
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it is not feasible to know how many PQ1 molecules can bind to the connexin protein based on 
the docking software. 
1.6 Treatment 
 
1.6.1 Tamoxifen treatment studies for breast cancer 
Tamoxifen is a nonsteroidal triphenylethylene derivative which competitively blocks the 
binding of estrogen to the estrogen receptor, thus considered to be an antiestrogen. Studies were 
conducted to test the efficacy of tamoxifen against breast cancer. A small randomized clinical 
trial of 3 years of tamoxifen versus no treatment demonstrated a survival advantage for ER+ 
patients who received tamoxifen (Delozier et al., 1986). In 1977, a pilot study was conducted to 
determine whether patients could tolerate 5 years of adjuvant therapy and whether metabolic 
tolerance would occur during long-term use of tamoxifen. No unusual side effects were observed 
and blood levels of tamoxifen and its metabolites remained stable (Tormey, 1984; Tormey, 
1987). In 1987, a Scottish trial showed an increase in survival rate of recurrent patients for breast 
cancer receiving tamoxifen treatment compared to controls. A 10-year study conducted by 
Nolvadex Adujvant Trial Organization (NATO) found a significant effect of 2 years of 
tamoxifen treatment on the disease free survival rate in patients with early breast cancer (Jordan, 
1994). From 1992-1997, the National Breast and Bowel Project (NSABP) randomized 13,388 
women into the Breast Cancer Prevention Trial (NSABP BCPT; P-1) who were at increased risk 
of breast cancer to either tamoxifen or placebo. The study showed a 49% reduction in overall 
invasive breast cancer risk and a 50% reduction in non-invasive breast cancer risk in women who 
received tamoxifen (Rashid, 2006). In 1998, tamoxifen was approved as a chemoprevention drug 
for breast cancer by the Food and Drug Administration (FDA), after NCI released the results of 
the Breast Cancer Prevention Trial (BCPT), a 6-year study of the drug. In BCPT, tamoxifen was 
found to reduce the incidence of breast cancer by 49 percent. Based on that study, FDA approved 
the drug for women at high risk of developing invasive breast cancer. High risk was defined as 
women of age 35 and older who have a 5-year risk of at least 1.67% (NCI, 2003).  
Tamoxifen was introduced as an antiestrogen and hence, it was used against breast cancer 
as estrogen potentiates breast cancer. But later studies were conducted to find if tamoxifen 
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affects pathways other than mediated through prevention of estrogen binding with estrogen-
responsive elements. Clinical response in breast cancer patients receiving tamoxifen daily for at 
least 3 months showed increased apoptosis and decreased proliferation using surrogate markers 
of apoptosis (Bcl-2) and mitosis (Ki-S1) (Keen et al., 1997; Cameron et al., 2000) Zhang and 
Shapiro found that tamoxifen induces apoptosis in MCF-7 cells by regulating p38 mitogen 
activated protein kinase (MAPK) (Zhang and Shapiro, 2000). These studies suggest that 
tamoxifen might be exerting effect on many proapoptotic pathways besides being an 
antiestrogen. 
 
1.6.2 Side effects of Tamoxifen  
In the breast, the antitumor effects of tamoxifen are due to ER antagonist activity, 
competitively blocking the binding of estrogen to ERs. Estrogen deprivation due to tamoxifen 
can also lead to unwanted side effects (Perez, 2007). Endometrial cancer risk was associated with 
tamoxifen therapy for breast cancer (odds ratio = 1.52; 95% confidence interval [CI] = 1.07-
2.17). Women with more than 5 years of exposure to tamoxifen had 4.06-fold greater odds of 
developing endometrial cancer than nonusers (95% CI = 1.74-9.47). Risk associated with 
tamoxifen use was stronger among heavier women than among thinner women, although trends 
did not differ statistically (P = .10) (Bernstein et al., 1999). A case-control study done at 
Netherlands found that the median time between the diagnoses of breast cancer and endometrial 
cancer was 34 (5-201) months and the relative risk of endometrial cancer for women who had 
ever been treated with tamoxifen compared with those who had not was 1.3 (Van Leeuwen et al., 
1994). Patients treated with tamoxifen experience hot flashes, night sweats, vaginal discharge, 
vaginal bleeding, gall stone formation (Day R, 1999; Day, 2001; Day et al., 2001; Vogel et al., 
2006). In premenopausal women, tamoxifen may result in bone loss. In a British study of 
tamoxifen on bone mineral density (BMD), it was found that BMD of premenopausal women 
decreased progressively in lumbar spine (p< .001) and in hip (p< .05) for women on tamoxifen 
compared to the placebo group (O'Regan et al., 2002). These more severe side effects contribute 
to the adverse risk: benefit profile associated with longer-term tamoxifen use, which limits 
adjuvant tamoxifen to 5 years (Fisher et al., 1996). 
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1.6.3 Combinational studies of tamoxifen for breast cancer  
Tamoxifen acts by inhibiting the binding of estrogen with the estrogen receptor, whereas 
aromatase inhibitors block the conversion of androgens to estrogen by aromatase enzyme, 
thereby causing estrogen deprivation. The third-generation aromatase inhibitors (AIs), letrozole, 
anastrozole and exemestane, have demonstrated superior efficacy to tamoxifen in large, 
randomized clinical trials in postmenopausal women with HR+ (hormone receptor positive) early 
breast cancer (Coombes et al., 2004; Boccardo et al., 2005; Howell A, 2005; Jakesz et al., 2005; 
Thurlimann et al., 2005). Analysis of the ATAC trial at a median follow-up time of 47 months 
demonstrated that after an additional follow-up period, anastrozole continued to exhibit superior 
efficacy than tamoxifen alone and in combination with anastrozole. This demonstrated by 
disease free survival (DFS), time to recurrence (TTR), and reduction in the incidence of 
contralateral breast cancer (CLBC) (Baum et al., 2003). The 5 year disease-free survival was 
significantly greater in the letrozole group (77.9%) than in the tamoxifen group (71.4%, hazard 
ratio for the primary end point, 0.81; 95% confidence interval), especially reducing recurrence at 
distant sites (hazard ratio, 0.73; 95% confidence interval). The 5-year estimates of disease-free 
survival were 84.0% in the letrozole group and 81.4% in the tamoxifen group (Thurlimann et al., 
2005). In another study the outcome showed that switching patients to adjuvant treatment with 
exemestane after 2 to 3 years of tamoxifen therapy was associated with a statistically and 
clinically significant improvement in disease-free survival, which included a reduction in the 
incidence of metastatic disease. DFS after 3 years of randomization was 91.5% (95% confidence 
interval, 90.0 to 92.7) in the exemestane group and 86.8% (95% confidence interval, 85.1 to 
88.3) in the tamoxifen group (Coombes et al., 2004). Overall, many studies indicate that 
aromatase inhibitors might gradually displace tamoxifen as the gold standard for adjuvant 
endocrine therapy (Perez, 2007).  
Raloxifene hydrochloride is a selective estrogen receptor modulator like tamoxifen that 
has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid 
metabolism, and blood clotting (Cummings et al., 1999). Trials of tamoxifen and raloxifen were 
done separately and a 33% and 59% reduction, respectively, in the relative risk of breast cancer 
was found; however, both the treatments cannot be compared because the participants in the 
tamoxifen and raloxifen study were pre-menopausal women and post-menopausal women, 
respectively (Cummings et al., 2009). A study of tamoxifene and raloxifene (STAR) program 
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was conducted to estimate the efficacy of raloxifene compared to tamoxifen. The study showed 
that both the drugs reduced the risk of developing invasive breast cancer by about 50% and 
women who took raloxifene and followed for 4 years showed 36% fewer uterine cancers and 
29% fewer blood clots (NCI, 2007). 
All these studies suggest that tamoxifen, despite being a drug of choice for the treatment 
of endocrine-responsive breast cancers, has some serious side effects. The treatment of 
tamoxifen depends on the risk:benefit ratio in an individual. However, combination of tamoxifen 
with another drug causing an increase in apoptosis of the cancer cells could be a potential 
therapy for the breast cancer. The combinational therapy could either decrease the 5-year 
treatment with tamoxifen or could help in negating the effects of tamoxifen. In the present study, 
we combined PQ1, a gap junctional activator with tamoxifen. Studies conducted with PQ1 alone 
showed an increase in GJIC, decrease in cell proliferation and colony growth assay in breast 
cancer cells. Furthermore, PQ1 also showed a 70% decrease in tumor growth in nude mice. 
Therefore, we investigated the effect of combinational treatment of tamoxifen and PQ1.  
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Chapter 2 -  Hypothesis and Objectives 
2.1 Hypothesis 
 
1. A decrease or loss in gap junctional intercellular communication can potentiate cancer 
formation 
2. Restoration of gap junctional intercellular communication can decrease tumor growth 
 
 
2.2 Objectives 
 
1. To determine the effect of an environmental pollutant, TCDD, on gap junctional 
intercellular communication in human mammary epithelial cells (HMEC) and MCF-7 
cells 
2. To screen for gap junctional activators 
3. To investigate the role of substituted quinolines, PQ1, on human breast cancer cell lines 
(in vitro) and nude mice (in vivo) 
4. To evaluate the combinational effect of PQ1 and tamoxifen  
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Figure 2.1  Schematic representation of the rationale and the questions being asked. 
Dark green boxes represent rationale and the three circles represent objectives. 
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Chapter 3 -  Regulation of gap junctional intercellular 
communication by TCDD in HMEC and MCF-7 breast 
cancer cells 
3.1 Abstract  
Previous studies suggest that many neoplastic tissues exhibit a decrease in gap junctional 
intercellular communication (GJIC). Many hydrocarbons and organochlorine compounds are 
environmental pollutants known to be carcinogenic. The effect of an organochlorine compound, 
TCDD, on GJIC in human breast cell lines has not been established. In the present study, we 
showed that TCDD causes an inhibition in the gap junctional activity in MCF-7 (breast cancer 
cells). In MCF-7 cells, an increase in the phosphorylated form of gap junctional protein, 
connexin 43 (Cx43), and PKC α was seen in the presence of TCDD. Gap junctional plaque 
formation was significantly decreased in MCF-7 cells in the presence of TCDD. 
Immunoprecipitation studies of PKC α showed that TCDD caused a significant 40% increase in 
the phosphorylated Cx43 in MCF-7 cells. TCDD also modulated the translocation of PKC α 
from the cytosol to the membrane and caused a 2-fold increase in the PKC α activity at 50 nM 
TCDD in MCF-7 cells. Calphostin C, an inhibitor of PKC α, showed a significant inhibition of 
PKC α activity in the presence of TCDD. Furthermore, TCDD also caused a decrease in the gap 
junctional activity and Cx43 protein in human mammary epithelial cells (HMEC). However, we 
observed a shift in the Cx43 plaques towards the perinuclear membrane in the presence of TCDD 
by confocal microscopy and Western blot. Overall, these results conclude that TCDD decreases 
GJIC by phosphorylating Cx43 via PKC α signaling pathway in MCF- 7 cells; however, TCDD 
decreases the GJIC by affecting the localization of Cx43 in HMEC. These new findings elucidate 
the differential mode of effect of TCDD in the downregulation of GJIC in HMEC and MCF-7 
cells. 
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3.2 Introduction  
Polycyclic aromatic hydrocarbons are ubiquitous environmental and food contaminants 
formed mainly during the incomplete combustion of organic materials (Blaha et al., 2002). 
Among these, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD), is a highly persistent 
environmental pollutant and a known human carcinogen (Safe, 1990, 1995). More than 2-fold 
increase in the incidence of breast cancer was found in female workers working in TCDD-
exposed chemical plant (Manz et al., 1991). TCDD was shown to alter mammary gland 
differentiation and increased susceptibility for mammary cancer in a carcinogen induced rat 
mammary cancer model (Jenkins et al., 2006). Many studies indicate the potential role of TCDD 
in regulating the activity of GJIC (Baker et al., 1995; Chipman et al., 2003; Sharovskaja et al. 
2004). But the effect of TCDD on the GJIC in human breast cells has not been studied.  
Gap junctional intercellular communication (GJIC) is formed by gap junctions (GJ), 
dynamic intercellular plasma membrane channels allowing the passage of small molecules (<1 
kD) between adjacent cells (Mesnil, 2002; Carystinos et al., 2002; Vine and Bertram, 2002). Gap 
junctions are formed by the interaction of two hemichannels (connexon) in the adjacent cells, 
which, in turn are made of six subunits of connexin (Cx) proteins (Carystinos et al., 2002). The 
structure of connexins includes four hydrophobic membrane-spanning domains, two extracellular 
loops, one cytoplasmic loop, and an amino and carboxyl terminus in the cytoplasm (Goodenough 
et al., 1988; Hertzberg et al., 1988; Yeager and Gilula, 1992; Knudsen and Wheelock, 1992). In 
a cell, GJIC is mainly regulated by the phosphorylation of the C-terminus of connexin proteins 
(Carystinos et al., 2002). The ability of TPA to inhibit GJIC has been associated with the 
activation of PKC (Lampe, 1994; Rivedal and Opsahl, 2001; Zampighi et al., 2005). Evidence 
demonstrated that PKC may inhibit gap junction channels by inhibiting gap junction assembly 
and channel gating (Tomasetto et al., 1993). PKC α overexpression has been shown to cause 
tumor growth, and tumor resistance to cytotoxic chemotherapy. In a study conducted on breast 
cancer patients, PKC activity was found significantly higher in breast tumor tissue compared to 
normal tissue from the same patient (O'Brian et al., 1989). Studies have shown that many 
neoplastic cells show fewer or dysfunctional gap junctions and have reduced GJIC (Trosko and 
Ruch, 1998). Many studies also suggest that the alteration in connexin expression is important, 
as their forced expression, following cDNA transfection, can promote cell density inhibition and 
reverse the tumor phenotype (Mesnil, 2002). Tumor growth of communication-deficient human 
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tumor cells, SKHep1, was significantly higher than cells transfected with cDNA encoding Cx32 
in athymic nude mice (Eghbali et al., 1991). Re-expression of hCx26 and hCx43 exhibited a 
classical tumor-suppressive behavior restoring growth-regulatory properties to metastatic 
mammary carcinoma cells and inducing differentiation (Hirschi et al., 1996). Consistently, these 
studies strongly suggest that the altered expression of connexins leads to loss of growth control 
and restoration of GJIC causes inhibition of cell proliferation thereby exhibiting tumor 
suppressive effect. Given the importance of GJIC in cancer, we used breast cancer as the model 
to test the effect of TCDD on GJIC. Cx43 is the most predominant form in breast epithelium and 
detected mostly in myoepithelial cells. Therefore, in our present study we observed the effect of 
TCDD on GJIC by measuring Cx43 expression. The strategy for the prevention and treatment of 
cancers is based on understanding the underlying mechanisms of carcinogenesis. Environmental 
pollutants have been shown to affect the GJIC but the mechanism still remains elusive. The aim 
of our study was to investigate how TCDD can affect the activity of GJIC in human breast cells. 
We directly examined the effect of TCDD on human breast cancer cells, MCF-7, and primary 
mammary epithelial cells, HMEC. Our study provides evidence showing that TCDD inhibits the 
GJIC through traditional and non-traditional pathways in cancerous and non-cancerous breast 
cells respectively. 
 
3.3 Material and Methods  
 
3.3.1 Cell lines and cell culture  
MCF-7 human breast cancer cell line was purchased from American Type Culture 
Collection (Manassas, VA) and HMEC from Cambrex (Rockland, MA). MCF-7 cells were 
grown in Minimal Essential Media (MEM) supplemented with Earl's salts, glutamine, 1 mM 
sodium pyruvate, 0.01 mM nonessential amino acids, antibiotic/antimycotic, and 1.5 g/L sodium 
bicarbonate. MCF-7 cells were enriched with 10% fetal bovine serum (Atlanta biologicals, 
Lawrenceville, GA). HMEC were grown in mammary epithelial growth medium supplemented 
with bovine pituitary extract from Cambrex (Rockland, MA). Calphostin C, an inhibitor of PKC 
α, was purchased from Calbiochem (NJ, USA) and dissolved in dimethyl sulfoxide (DMSO).  
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3.3.2 Gap junctional activity - scrape load/dye transfer (SL/DT) assay  
Cells were grown to 90% confluency on coverslips, dosed with 10, 50, 100 and 200 nM 
of TCDD and DMSO for an hour. Similarly, MCF-7 cells were dosed with calphostin C (100 
nM) for 30 min and media were aspirated and cells were treated with varying concentrations of 
TCDD for an hour. TPA was used as a positive control for the phosphorylation of PKC α. Cells 
were washed three times with PBS. The 2.5 µl mixture of 1% (w/v) Lucifer yellow and 0.75% 
(w/v) of Rhodamine-dextran was added in the center of the coverslip. Two cuts crossing each 
other in the center of the coverslip were made. This cut allows the transfer of the Lucifer yellow 
dye as well as rhodamine-dextran in the cells at the line of cut. However, the passage of the 
Lucifer yellow dye from the injured cells to the membrane-intact cells is through gap junctions. 
After 3 min, cells were washed three times with PBS and incubated at 37°C in tissue culture 
media for 20 min. The cells were then washed with PBS and fixed in 2.5% paraformaldehyde for 
10 min. Cells were mounted on a slide, sealed and visualized under a fluorescence microscope at 
10Χ objective.  
 
3.3.3 Western blot analysis 
After reaching 90% confluency, MCF-7 cells and HMEC were harvested from a 75 cm2 
flask and 25 cm2 flask respectively. Cells were grown in a phenol red-free DMEM with 5% 
charcoal dextran stripped serum, overnight. Cells were dosed with 0, 10, 50, 100, and 200 nM of 
TCDD and DMSO for an hour. DMSO was used as a solvent to dissolve TCDD. Cells were 
harvested in lysis buffer containing appropriate protease inhibitors. 30 µg of whole cell extract 
was resolved by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to 
nitrocellulose membrane (Midwest Scientific, Saint Louis, MO). Nitrocellulose membrane was 
blocked in 5% milk for an hour at room temperature and then incubated with monoclonal mouse 
anti-PKC α antibody at 1:500 dilution (Santa Cruz Biotechnologies, Santa Cruz, CA), 
monoclonal mouse anti-Cx43 at 1:500 dilution (Fred Hutchinson, Seattle, WA), anti-phospho-
Ser 368 Cx43 antibody at 1:500 dilution (Cell signaling technology, MA, USA ) and rabbit anti-
actin antibody at 1:1000 dilution (Sigma-Aldrich, Saint Louis, MO). The signal was detected by 
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enhanced chemiluminescence system (Pierce, Rockford, IL, USA). Lamin B1 antibody was used 
(ZL-5, Abcam, MA, USA) at 1:500 dilution to confirm the pure extraction of nuclear and 
cytoplasmic fraction. 
 
3.3.4 Immunoprecipitation and translocation studies 
  MCF-7 cells were dosed with 10, 50, 100, and 200 nM TCDD and DMSO for an hour. 
Cells were harvested and 1 mg of whole cell extract was precleared with protein A/G-agarose 
beads (Santa Cruz Biotechnology, CA, USA) for 30 min. Then, samples were centrifuged at 
2000 rpm for 5 min. Supernatant was collected and incubated with the anti-PKC α antibody at 
1:2000 dilution overnight at 4°C. Samples were centrifuged at 2000 rpm for 5 min and pellet was 
washed three times with lysis buffer. Samples were run on 10% SDS-PAGE and immunoblotted 
with anti-Cx43 (Chemicon International Inc., Temecula, CA), anti-phospho-Ser 368 Cx43 and 
anti-PKC α antibodies. For translocation studies, MCF-7 cells were dosed with 10, 50, 100, and 
200 nM TCDD. Cells were lysed with MgCl2 and centrifuged at 35,000 rpm for 60 min at 4°C. 
Pellet was separated from the supernatant and resuspended in lysis buffer. Samples were 
sonicated and whole cell extracts were subjected to Western blot analysis. Nitrocellulose 
membranes were immunoblotted with anti-Cx43 and anti-actin antibodies. In HMEC, 
cytoplasmic and nuclear fractions were separated by using NE-PER kit (Cat # 78833, Pierce, 
Rockford, IL, USA).  
 
3.3.5 Measuring kinase activity 
  The whole cell extract was obtained as described for Western blotting. PKC α activity 
was measured using Promega kinase activity assay kit (Promega, Madison, WI). The procedure 
was followed as recommended by the manufacturer. Results were visualized under UV light. 
 
3.3.6 Immunofluorescent labeling and confocal microscopy 
  Cells were grown on coverslips in 6-well plates in phenol red-free DMEM media plus 5% 
charcoal dextran stripped serum overnight. Cells were treated with 10, 50, 100, 200 nM of 
TCDD and DMSO for 1 hr. Cells were first fixed with 2.5% paraformaldehyde for 10 min and 
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then neutralized with 50 mM glycine for 5 min. The cells were lysed with 0.15% Triton X-100 
for additional 20 min. After washing with PBS, cells were blocked with 3% BSA in PBS for 2 hr 
and then incubated with primary antibodies, mouse anti-PKC α and rabbit anti-Cx43 antibodies 
(Chemicon International Inc, Temecula, CA), for 15 hr at 4°C. Following this step, cells were 
incubated with anti-mouse and anti-rabbit Alexa fluor 488 and 568 (Molecular probes, Eugene, 
OR, USA) for 2 hr at room temperature respectively. Samples were sealed and analyzed by a 
confocal microscope (Carl Zeiss LSM 510 META, Narashige, MN). 
 
3.4 Results  
 
3.4.1 Effect of TCDD on gap junctional activity 
We examined the effect of TCDD on the GJIC in MCF-7 cells. By using scrape load/dye 
transfer (SL/DT) assay, the transfer of Lucifer yellow dye from one cell to another indicates 
GJIC and rhodamine-dextran is often used as a control as it cannot pass through intact plasma 
membrane. We observed a dose-dependent decrease in GJIC in presence of TCDD (Figure 3.1). 
10 and 100 nM TCDD can inhibit Lucifer yellow dye transfer in MCF-7 cells (Figure 3.1A). 
MCF-7 cells treated with calphostin C and TCDD showed restoration of gap junctional activity 
at 10, 50, 100 nM of TCDD. At 200 nM TCDD, inhibition in GJIC was observed even in the 
presence of calphostin C (Figure 3.1B).  
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Figure 3.1  Scrape load/dye transfer assay (SL/DT) 
A) MCF-7 breast cancer cells were seeded on coverslips in a 6-well plate until 90% confluency. 
Cells were then dosed with TCDD at various concentrations for an hour, loaded with dye, 
scraped, fixed in paraformaldehyde and viewed under fluorescence microscope. The cuts were 
made with a sharp blade in an X- fashion on the coverslip after the addition of the dye. Green 
fluorescence indicates Lucifer yellow, transferring from cell to cell only through gap junctions. 
Arrows indicate the line of cut. At 100 nM TCDD, there was a decrease in the transfer of Lucifer 
yellow dye away from the line of cut. Note: the difference in the Lucifer yellow dye transfer 
between the control and 100 nM TCDD. DMSO is a solvent used to dissolve TCDD. B) MCF-7 
cells were treated with calphostin C, PKC α inhibitor, for 30 min and later with TCDD for 1 hr. 
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MCF-7 cells were prepared for the SL/DT assay as described above. Note: the increase in 
Lucifer dye transfer in 10, 50, and 100 nM TCDD pre-treated with calphostin C as compared to 
10 and 100 nM TCDD alone without calphostin C. However, at 200 nM TCDD Lucifer yellow 
dye transfer is inhibited. 
 
Furthermore, we examined the structural GJIC formation. Figure 3.2A shows the effect 
of TCDD on the Cx43 plaque formation in MCF-7 cells. 10-200 nM TCDD inhibited Cx43 
plaque formation compared to control without TCDD or DMSO treatment in MCF-7 cells. On 
the other hand, in the presence of calphostin C, Cx43 plaque formation was seen at 10, 50, 100 
nM TCDD but not at 200 nM TCDD (Figure 3.2B). 
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Figure 3.2  Confocal microscopy showing the effect of TCDD on the Cx43 plaque 
formation. 
 A) MCF-7 cells were dosed with 0, 10, 50, 100 and 200 nM TCDD for an hour. B) MCF-7 cells 
were treated with calphostin C (100 nM) for 30 min prior to the dosing of TCDD for an hour. 
Note: the presence of Cx43 plaques in 50 and 100 nM TCDD. However, at 200 nM TCDD 
Cx43 plaque formation was completely inhibited. 
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3.4.2 Effect of TCDD on the expression of Cx43 and PKC α 
Cx43 is phosphorylated at multiple serine residues. One of the serine residues, serine 368, 
of Cx43 has been shown to be phosphorylated by PKC (Lampe and Lau, 2000). Therefore, the 
expression of both phospho-Ser 368 Cx43 and PKC proteins in the presence of TCDD was 
examined. We found that 10-200 nM TCDD caused an increase in phospho-Ser 368 Cx43 
(Figure 3.3A). Similarly, a significant 40% increase in PKC α expression at 200 nM TCDD 
treatment compared to control or DMSO was seen (Figure 3.3B). However, 10 nM TCDD for 1 
hr was not significant to cause an increase in PKC α expression. 
 
A. 
                   
 
 
 
 B. 
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Figure 3.3  Expression profile of phospho-Ser 368 Cx43 and PKC α in presence of TCDD in 
MCF-7 cells. 
A) Western analysis of phospho-Ser 368 Cx43 in MCF-7 cells dosed with different 
concentrations of TCDD. Actin is used as a loading control. A histogram representing three 
independent experiments is provided showing the increase in phospho-Ser 368 as a relative 
percentage of control, *p < 0.01. pCx43 is phosphorylated serine 368 Cx43. B) The effect of 
TCDD on the PKC α expression in MCF-7 cells. Graphical presentation of three independent 
experiments with the standard deviation is shown. DMSO is the vehicle used to dissolve TCDD. 
C = Control, DM = DMSO, *p < 0.05. 
 
3.4.3 Translocation studies of PKC α in MCF-7 cells 
Activation of PKC isoforms results in changes in their subcellular location. We found 
that TCDD increases the translocation of PKC α from the cytosol to the membrane. 10 nM 
TCDD was sufficient to translocate PKC α from the cytosol to the membrane (Figure 3.4A, lane 
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3), and 100 nM TCDD completely translocates PKC α to the membrane (Figure 3.4A, lane 5). 
This means that TCDD is involved in the activation of PKC α. The results were also confirmed 
by immunofluorescence studies (Figure 3.4B). Immunofluorescent PKC α was localized around 
the plasma membrane in TCDD treatment compared to control or DMSO. In HMEC, PKC α was 
not observed. Other classical PKCs (PKC β and PKC γ) were not affected by TCDD in both cell 
types (Appendix A, Figure S1). 
 
 
                           
B. 
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C.                                                                                        D. 
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Figure 3.4  Localization of PKC α and the interaction of PKC α and Cx43. 
 A) Western blots showing the effect of TCDD on translocation of PKC α from the cytosol to the 
membrane in MCF-7 cells. Separation of cytosolic and membrane fractions was performed as 
described in Materials and Methods. 100 nM TCDD-treated cells caused a significant 
translocation of PKC α from the cytosolic fraction to the membrane fraction. Graphical 
representation of three independent experiments with ±SD, *p < 0.05. B) Immunofluorescence 
showing the localization of PKC α in the presence of TCDD in MCF-7 cells. Cells were treated 
with 10, 50, 100 and 200 nM TCDD for 1 hr. Immunofluorescent labeling was performed as 
described in Materials and Methods. PKC α was labeled with Alexa fluor 488 for 2 hr and then 
the cells were washed, sealed and observed under 40X oil objective confocal microscope, pin 
hole = 0.65 µm. Green fluorescence was seen around the cell membrane as the concentration of 
TCDD was increased. C) Interaction of PKC α and Cx43 in MCF-7 cells. Immunoprecipitated 
PKC α was subjected to Western blot analysis. The nitrocellulose membrane was immunoblotted 
against Cx43. P0 and P2 forms of Cx43 are shown separately. Graphical presentation of three 
experiments with standard deviation and statistical significance, *p < 0.05. D) Interaction of PKC 
α and pCx43 in MCF-7 cells. Immunoprecipitated PKC α was transferred to nitrocellulose 
membrane and immunoblotted with pCx43. A histogram representing three independent 
experiments, *p < 0.01. 
 
3.4.4 Immunoprecipitation studies showing interaction of phosphorylated Cx43 with 
PKC α 
PKC α was immunoprecipitated from MCF-7 cells using Protein A/G-agarose beads and 
anti-PKC α antibodies (Figures 3.4C, D). The nitrocellulose membrane was probed with anti-
Cx43 antibodies. The results showed a significant 40% increase in P2 form of Cx43 upon 
activation by 10 and 50 nM of TCDD in MCF-7 cells (Figure 3.4C). However, treatments of 100 
and 200 nM TCDD only have a slight interaction of PKC α and Cx43 (Figure 3.4C lane 5, 6). 
This experiment was repeated using anti-phospho-Ser 368 Cx43 antibody (Figure 3.4D). 
Similarly, we found an increase in phospho-Ser 368 Cx43 at 10 and 50 nM TCDD. This suggests 
that in the presence of TCDD, PKC α phosphorylates Cx43 in MCF-7 cells.  
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3.4.5 Effect of TCDD on the PKC enzyme activity  
PKC enzyme activity assay was performed with samples treated with calphostin C in the 
presence of TCDD and, TCDD alone. Promega PKC peptide substrate system was used to 
measure the PKC activity (Figure 3.5A). Fluorescence peptides separate according to charges. 
Phosphorylated peptides migrate towards anode. The results demonstrated that treatment of 50 
nM TCDD significantly increased PKC enzyme activity by 2-fold in TCDD alone treated MCF-7 
cells (Figure 3.5B). In the presence of calphostin C, PKC activity was significantly reduced at 
10, 50, 100 nM TCDD compared to the control. However, at 200 nM TCDD, PKC enzyme 
activity was 20% more than the control. 
                A. 
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Figure 3.5  The effect of TCDD on PKC enzyme activity in MCF-7 cells. 
 A) Cells were dosed with 10, 50, 100 and 200 nM of TCDD. Whole cell extract was used. PKC 
enzyme activity was performed according to the manufacturer's recommendation. Reaction 
mixtures were separated on agarose gel according to the charges of the substrate. Excision of the 
phosphorylated bands was measured using photospectrometer at 570 nm. Graphical 
representation of three experiments with ±SD and statistical significance, *p < 0.05. B) Cells 
were dosed with calphostin C for 30 min prior to 10, 50, 100 and 200 nM TCDD treatment for 1 
hr. PKC enzyme activity was performed. Note: the significant decrease in the PKC activity in the 
presence of calphostin C treated with 10, 50 and 100 nM TCDD. However, at 200 nM TCDD, 
the PKC activity restored back indicating that the effect of 200 nM TCDD on PKC activity 
cannot be inhibited with 100 nM calphostin C. TPA was used as a positive control for PKC 
activity. Positive indicates the positive control provided by the manufacturer, which includes 
using purified PKC enzyme. Negative control includes the reaction mixture excluding any 
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sample/PKC enzyme. Graphical representation of three experiments with ±SD and statistical 
significance, *p < 0.01. 
 
3.4.6 Effect of TCDD on primary mammary epithelial cells 
Previous studies have indicated that the expression of Cx43 or gap junctional activity of 
normal cells is higher than neoplastic cells (Hirschi et al. 1996; Trosko and Ruch 1998). Since 
breast cancer cells have a lower level of Cx43 and gap junctional activity, we examined the 
effect of TCDD on normal breast cells, HMEC. Interestingly, higher concentration of TCDD is 
required to inhibit dye transfer. 200 nM TCDD caused a significant decrease in GJIC compared 
to control in HMEC (Figure 3.6A). Furthermore, 200 nM TCDD can cause a decrease in Cx43 
(Figure 3.6B). Surprisingly, confocal microscopy showed the presence of Cx43 aggregates in the 
perinuclear area in the presence of 10-200 nM of TCDD (Figure 3.7A) compared to the Cx43 
plaques on the membrane in the controls. Further evidence was provided by nuclear extraction of 
HMEC. 10 nM TCDD can cause an increase of Cx43 expression in the nuclear fraction 
compared to control (Figure 3.7B). However, at 200 nM TCDD, Cx43 expression was 
completely reduced in both cytoplasmic and nuclear fractions. Blots were stripped and Lamin B1 
expression was observed only in the nuclear fraction and not in the cytoplasmic fraction (Figure 
3.7B). Thus, these findings show for the first time that TCDD affects gap junctional activity in 
HMEC through different mechanism than MCF-7 cells. 
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B. 
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Figure 3.6  Scrape load dye transfer assay (SL/DT) and expression of Cx43 in HMEC. 
A) HMEC were seeded in a 6-well plate and dosed with different concentrations of TCDD for an 
hour. SL/DT assay was performed as described in Figure 3.1A. Pictures depict three independent 
experiments. B) Effect of TCDD on Cx43 expression. Cells were treated with DMSO and 10, 50, 
100, 200 nM TCDD for 1 hr. A significant decrease in Cx43 at 200 nM TCDD compared to the 
control was observed, *p < 0.05. 
 
A. 
 
 
 
 
 
 
B. 
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Figure 3.7  Confocal microscopy showing the effect of TCDD on Cx43 plaque formation 
and the localization of Cx43 in HMEC. 
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A) Cx43 plaque formation in the presence of 0, 10, 50, 100 and 200 nM TCDD. Cells were 
stained with DAPI (blue nuclear stain) and anti-Cx43 mouse antibody (red). Images were seen 
under 40X oil objective lens, pin hole = 0.76 µm and arrows indicate the plaque formation. 
Pictures represent three different experiments. B) Cx43 expression in nuclear and cytoplasmic 
fraction dosed with different concentrations of TCDD. All the Western blots are a representative 
of three individual experiments. Lamin B1 was used as a nuclear marker showing the separation 
of the nuclear and cytoplasmic fraction. Graphical representation of three experiments with ±SD 
and statistical significance, *p < 0.01 is shown. 
 
3.5 Discussion  
TCDD is a human carcinogen. It has been implicated as a reproductive toxin in humans, 
including its potential for breast cancer (Adami et al., 1995). Studies have been conducted to 
understand the risk of cancer in the presence of TCDD. TCDD is not a genotoxic, therefore, its 
exposure can affect many downstream pathways. We showed for the first time that TCDD has a 
differential effect on GJIC in primary mammary epithelial cells, HMEC and breast cancer cells, 
MCF-7. Baker et al. (1995) demonstrated that TCDD inhibits GJIC in the in vivo target of its 
tumor promoting effect and this effect may, in part, be directed through Ah receptor in primary 
culture of rat hepatocytes. In the present study, SL/DT was used to measure the activity of GJIC. 
Lucifer yellow dye (MW 457.2) passes from one cell to another through gap junctions whereas 
rhodamine-dextran (MW 10,000) passes only through injured plasma membrane. We found a 
decrease in the Lucifer dye transfer between the cells even in the presence of 10 and 100 nM of 
TCDD in MCF-7 cells (Figure 3.1A). This suggests that the gap junctional activity between the 
MCF-7 cells is decreased in the presence of TCDD. Plaques are the functional aggregations of 
many gap junctions on the plasma membrane. Clustering of gap junction channels into plaques is 
required for functional cell coupling. Since Cx43 is the most predominant form of connexin in 
breast epithelium, the effect of TCDD on Cx43 plaque formation was observed. Cx43 plaques 
were decreased in the presence of 10-200 nM TCDD in MCF-7 cells (Figure 3.2A). A complete 
loss in the Cx43 plaque formation was seen from 50-200 nM TCDD in MCF-7 cells. This 
suggests that TCDD affects the GJIC by affecting the formation or degradation of Cx43 plaques 
in MCF-7 cells.  
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Various tumor-promoting agents (Ruch et al., 2001) decrease GJIC, either by suppressing 
Cx expression or by inducing post-translational modifications such as phosphorylation, a process 
that is closely related to cellular processes such as trafficking, assembly/disassembly, gating of 
gap junction channels, and altered susceptibility to degradation (Lampe and Lau, 2000). The 
carboxy-terminus of Cx43 contains several serine and tyrosine phosphorylation sites, suggesting 
that this region of the molecule contains a complex array of potential regulatory sites (Lampe 
and Lau, 2000). Therefore, to understand the decrease in the gap junction activity by TCDD in 
MCF-7 cells, we investigated the phosphorylation of Cx43. Phospho-Ser 368 Cx43 antibody was 
specifically used to detect the phosphorylation of Cx43. PKC has been shown to phosphorylate 
Cx43 at serine 368 carboxyl terminal in vitro (Lampe et al., 2000; Saez et al., 1997; Shah et al., 
2002). We found an increase in phospho-Ser 368 Cx43 in the presence of 10-200 nM TCDD in 
MCF-7 cells (Figure 3.3A). Since an increase was seen in the phosphorylated form of Cx43 in 
MCF-7 cells, we examined the expression of kinases in the presence of TCDD. PKC α was 
found to be significantly increased in the presence of TCDD in MCF-7 cells (Figure 3.3B). It 
could be due to the effect on the transcriptional, post-transcriptional, or translational level. Early 
observations that PKC isozymes are activated by tumor promoting phorbol esters (Castagna et 
al., 1982) suggested a key role for PKC in tumor promotion and progression (Mackay and 
Twelves, 2003). Increased levels of PKC have been associated with malignant transformation in 
a number of cell lines including breast (O'Brian et al., 1989), lung (Takenaga and Takahashi, 
1996) and gastric carcinomas (Schwartz et al., 1993). In vitro studies suggest a positive 
correlation between elevated PKC levels and both the invasive and chemotactic potential of 
human breast cancer cell lines (Blobe et al., 1994). 
To confirm the phosphorylation of Cx43 by PKC α, we examined the effect of TCDD on 
the activation and interaction of PKC α with Cx43. Among others, diacylglycerol and Ca2+ are 
known to activate PKC by translocating it from the cytoplasm to the membrane and this report 
showed that TCDD is an activator of PKC α in MCF-7 cells. We found an increase in the 
translocation of PKC α from the cytosol to the membrane under the effect of TCDD in MCF-7 
cells (Figure 3.4A). The translocation of PKC α promotes the interaction of PKC α and Cx43 and 
subsequently the phosphorylation of Cx43. Translocation studies were further confirmed by 
confocal microscopy showing the localization of PKC α on the membrane in the presence of 
TCDD (Figure 3.4B). Immunoprecipitation studies showed an increase in the phosphorylated 
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form of Cx43 with an equal amount of PKC α being pulled out (Figures 3.4C, D). Interaction 
between PKC α and the phosphorylated form of Cx43 was increased significantly at 10 and 50 
nM TCDD; however, interaction was decreased at 100 and 200 nM TCDD. Our study supports 
previous studies that other potential PKCs sites might be involved in regulating assembly or 
degradation of gap junctions and channel behavior (Lampe and Lau, 2004). PKC has received 
considerable attention because PKC activators, which promote tumorigenesis, both increase 
Cx43 phosphorylation and decrease GJIC in a number of different cell types (Berthoud et al., 
1992; Brissette et al., 1991; Lampe, 1994; Reynhout et al., 1992). 
To confirm the functionality of PKC α, an enzyme activity assay was performed. We 
observed an increase in the enzymatic activity of PKC α in the presence of TCDD (Figure 3.5A). 
Cells treated with 100 nM TCDD did not show further increased PKC enzyme activity. This 
suggests that TCDD may activate other GJIC-mediated pathways that are also involved in the 
inhibition of GJIC. Calphostin C, an inhibitor of PKC α, was used to provide further evidence 
that TCDD mediated inhibition of gap junctional activity involves PKC α pathway. SL/DT assay 
showed the restoration of Lucifer dye transfer in MCF-7 cells in the presence of calphostin (100 
nM) followed by TCDD (Figure 3.1B). Confocal microscopy also showed the presence of Cx43 
plaques in the presence of TCDD in MCF-7 cells pre-treated with 100 nM calphostin C (Figure 
3.2B). A significant decrease in the PKC enzyme activity was observed in the presence of 
calphostin C (100 nM) in TCDD-treated MCF-7 cells (Figure 3.5B). All the experiments 
performed with calphostin C showed the restoration of the effect of TCDD at 200 nM in MCF-7 
cells. It can be concluded that when TCDD is double the concentration of calphostin C, the 
inhibitory effect of calphostin C on TCDD-mediated PKC α pathway is lost. However, 
calphostin C (100 nM) was sufficient enough to block the effect of 10, 50 and 100 nM TCDD 
confirming that the TCDD-mediated inhibition of GJIC involves PKC α pathway. 
To determine the effect of TCDD on non-cancerous human breast cells, primary human 
mammary epithelial cells were used. The dye transfer was tremendously reduced at 200 nM 
TCDD in HMEC (Figure 3.6A). Higher dose of TCDD caused a decrease in GJIC in HMEC 
compared to MCF-7 cells could be due to the fact that control HMEC exhibited more GJIC than 
control MCF-7 cells. This confirms the earlier studies suggesting a decrease in GJIC in 
cancerous cells compared to normal primary cells of the same tissue (Hirschi et al., 1996). 
Exposure of TCDD inhibits GJIC in both cell types, cancerous and non-cancerous cells. 200 nM 
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TCDD caused a decrease in the Cx43 expression (Figure 3.6B). This exhibits two different ways 
of regulation of GJIC by TCDD by phosphorylation of Cx43 in MCF-7 cells and by decrease in 
the expression of Cx43 in HMEC. Interestingly, PKCs expressions are not upregulated in control 
HMEC as in MCF-7 cells. In HMEC, a different effect of TCDD compared to MCF-7 cells was 
observed on the Cx43 plaque localization. In the presence of 10-200 nM TCDD, Cx43 plaques 
were redistributed from the plasma membrane to the perinuclear area in HMEC (Figure 3.7A). 
This effect could be due to the effect on the trafficking of Cx43 in HMEC. This suggests that 
TCDD causes the movement of Cx43 from the membrane to the perinuclear region or prevents 
the movement of Cx43 to the membrane. The pathways involved in the trafficking of Cx43 are 
not fully understood. Even though Cx43 plaques shifted to the perinuclear area supported by the 
appearance of Cx43 in the nuclear fraction at 10 nM TCDD, we still observed GJIC activity in 
HMEC by SL/DT. This could be explained by the presence of other connexin proteins, Cx26 and 
Cx32 in HMEC which can form homomeric or heteromeric GJs. To further provide evidence for 
the redistribution of Cx43 to the perinuclear area, we isolated nuclear and cytoplasmic fractions. 
Interestingly, Cx43 appears in the nuclear fraction and diminishes completely in the cytoplasmic 
fraction in the presence of 100 and 200 nM TCDD (Figure 3.7B). The expression of a nuclear 
protein, Lamin B1, was measured in the nuclear and the cytoplasmic fraction. Lamin B1 was 
detected only in the nuclear fraction confirming that there was no leakage of the nuclear proteins 
in the cytoplasmic fraction during the extraction procedure (Figure 3.7B). The differences in the 
level of Cx43 expression (Figure 3.6B) and nuclear and cytoplasmic fraction could be explained 
in part by HMEC are slow growing cells, being the primary cells, which can be grown to four 
passages without change in morphology. Therefore, minimal number of cells was used for 
nuclear extraction and the level of protein for both nuclear and cytoplasmic fractions was low, 
and another explanation is that the process of extraction might have led to the further loss of 
proteins. 
In conclusion, TCDD is an environmental pollutant which affects GJIC in human breast 
cells. This report adds to the previous information that GJIC plays a vital role in breast cancer. 
The results provide evidence that TCDD inhibits GJIC through traditional and non-traditional 
pathways. The summary of the results observed in MCF-7 cells has been shown in Figure 3.8. In 
cancer cells, PKC α is upregulated and thus TCDD inhibits GJ through PKC α translocation and 
phosphorylation of Cx43. However, in non-cancerous cells such as primary mammary epithelial 
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cells, TCDD also inhibits GJ through a novel pathway, redistribution of Cx43 to the perinuclear 
fraction. In the absence of the changes in protein kinases, TCDD mediates the localization of 
Cx43 in normal mammary cells. This study provides the molecular mechanism showing how 
TCDD affects gap junctions. The findings reveal the potential risk of exposure to environmental 
pollutants like TCDD on the normal breast epithelium and cancerous breast tissue using breast 
cells. 
 
Figure 3.8 Proposed pathway showing the effect of TCDD on GJIC in MCF-7 cells. 
TCDD increases the expression and activates PKC α, causing its translocation from cytosol to 
the membrane. Activation of PKC α causes phosphorylation of Cx43 on the plasma membrane, 
thereby decreasing the gap junctional activity. 
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Chapter 4 -  Antitumor effect of substituted quinolines in 
breast cancer cells 
4.1 Abstract  
Cancer in part is caused by the disruption in cell homeostasis, affecting the ability to 
respond to extracellular signals, triggering some intracellular events which affect the gap 
junctional intercellular communication (GJIC). Cancer cells have reduced or altered GJIC 
capacity. One feasible approach to reduce growth of cancer cells is to enhance/alter GJIC. The 
capability of cells to communicate through gap junction is negatively related to their growth 
activity. A computational docking study showed that a new class of substituted quinolines (code 
name: PQs) has a relatively high binding to gap junction protein, connexin 43. Thus, PQs were 
used in this study to find their effect on human breast cancer cells.  Scrape load/dye transfer  and 
colony growth assay were  performed to measure GJIC and determine the effect of the PQ 
compounds on the colony formation in human normal mammary epithelial cells (HMEC) and 
breast cancer cells, respectively. The results showed that PQs have a significant antitumor effect 
in human breast cancer cells compared to control without treatment or normal mammary 
epithelial cells. 200 nM PQ1 showed a 30% increase in the GJIC in T47D cells; however, there 
is no effect of PQ treatment on GJIC in normal mammary epithelial cells. In addition to an 
increase in GJIC, 80-95% growth attenuation was observed by PQ1 in colony growth assay. 
Moreover, an increase in caspase 3 with PQ-treated cells was observed, suggesting possible 
involvement in apoptosis. The results show that PQ1 compound have a promising role in 
exerting antitumor activity in human breast cancer cells. The treatment with PQ1 in T47D cells 
causes an increase in GJIC activity and active caspase 3, and a decrease in colony growth and 
cell viability. Substituted quinolines have demonstrated to activate gap junction activity and 
subsequently decrease colony and tumor growth. 
 
 
77 
 
4.2 Introduction  
 Breast cancer is the most common cancer in women worldwide and mortality from 
breast cancer is consistently due to tumor metastasis (Jemal et al. 2007). Progress in 
understanding the etiology of this disease and developing therapies has been slow due to multiple 
deregulations of various genes. The additive effects against mammary tumor cells might be 
achieved by combining anti-tumor agents directed against one or more altered mechanisms in 
cancer.   
Cancer cells exhibit many defects in cell communication that contribute to the loss of 
tissue homeostasis (excess cell proliferation, invasion, and metastasis) (Loewenstein 1979; 
Loewenstein and Kanno 1966; Trosko et al. 1990; Wilgenbus et al. 1992; Yamasaki and Naus 
1996). Intercellular communication in many organs is maintained via intercellular gap junction 
channels (GJIC). Gap junctions are the only communicating junctions found in animal tissues, in 
all species, which are responsible for the direct traffic of ions and molecules with molecular 
weights less than 1,200 Da (Martin and Evans 2004; Musil et al. 2000). These traffic ways are 
formed by the interaction between two hemichannels on the surface of opposing cells. 
Hemichannels are formed by the association of six proteins, the connexins. Because of the 
importance of intercellular junctions in the maintenance of the cellular homeostasis, the 
modulation of intercellular junctions and expression of connexin seems to be involved in 
carcinogenesis (Dubina et al. 2002; Holder et al. 1993; Ruch 1994). 
 Electrophysiological measurement and dye-transfer studies in vivo have shown that 
signal transmission through GJIC can be altered by a number of molecules (Bruzzone et al. 
1996). Electron crystallography studies demonstrate that the dimension of the pore of gap 
junction channel varies from 40 Å in the cytoplasm to 15 Å at the membrane boundary with the 
extracellular gap (Foote et al. 1998). The reported low density structure (Makowski et al. 1977) 
only provides a general shape of the channel proteins. A recombinant gap junction was 
constructed, (Unger et al. 1999) which allows the computational docking studies of the channel 
proteins with small molecules.   
Several small organic molecules, such as caffeic acid phenethyl ester (CAPE) (Na et al. 
2000), sodium 4-phenylbutyrate (Ammerpohl et al. 2004), Liarozole (Acevedo and Bertram 
1995), lycopene (Livny et al. 2002), and lovastatin (Ruch et al. 1993), have been reported for up-
regulation or restoration of GJIC. CAPE is an active ingredient in honeybee propolis and has 
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antiviral, anti-inflammatory and anticancer properties (Bhimani et al. 1993). The effective 
concentration of CAPE is 17 µM in restoring GJIC and phosphorylation of Cx43 in WB-ras2 
cells (Na et al. 2000). 4-Phenylbutyrate enhances GJIC in glioblastoma cells and consequently 
increases the efficiency of the bystander killing effect of HSV-tk suicide gene/ganciclovir 
technology (Ammerpohl et al. 2004). Phase I/II dose-escalating trial of lycopene in biochemical 
relapsed prostate cancer patients did not result in any discernible response in serum PSA (Clark 
et al. 2006). A phase II study of liarozole in advanced non-small cell lung cancer showed that it 
is ineffective as single agent therapy (O'Byrne et al. 1998). Lovastatin, an inhibitor of cellular 
cholesterol synthesis, has an IC50 value of ~8 µM over 72 hours against MCF-7 mammary cancer 
cells (Wei et al. 2007). Hence, new GJIC enhancers are needed, and the study of the mechanism 
of restoring GJIC would provide information for the design of selective GJIC enhancers. The 
restoration of GJIC mechanism may provide potential targets for anticancer therapy. 
In search of new activators that enhance GJIC, potential interactions of a number of 
substituted quinolines (code name PQs) with the partial crystal structure of gap junction 
(Fleishman et al. 2006; Makowski et al. 1977; Veenstra 2003) using Autodock computational 
docking software (Goodsell and Olson 1990; Morris et al. 1996; Morris 1998), was examined. 
Dr. Duy H. Hua’s lab observed bindings of PQs to the inert core of the hexameric hemichannel 
of gap junctions. In one of the minimum energy (-0.7 kcal/mol) bound structures, interactions 
(closed contact) between CF3 group of PQ1 and H-N of Leu144 of connexin (2.5 Å), and OCH3 
group of PQ1 and CH2 of Phe81 of connexin (2.0 Å) are found. Consequently, Dr. Hua 
synthesized this class of quinolines and studied their GJIC and anticancer activities. PQ analogs 
were synthesized via a modification of the reported protocol (LaMontagne et al. 1982a; 
LaMontagne et al. 1982b; Lauer 1946) starting from 4-acetaminoanisole (compound 6), and the 
synthetic sequence is depicted in Scheme 1.   
Tumor cells have reduced or altered GJIC capacity (Eghbali et al. 1991). It has been 
shown that the drug sensitivity was enhanced in Cx 43 overexpressing tumor cells (Huang et al. 
2001). Cancer cells are characterized by the lack of growth control, by the inability to terminally 
differentiate and by resistance to apoptosis. Various oncogenes (e.g. ras, raf, neu, src, mos) 
down-regulate GJIC while several tumor suppressor genes can up-regulate GJIC (Na et al. 2000; 
Ruch et al. 1993; Zhang et al. 1994). Transfection of gap junction genes, connexins, into GJIC-
deficient tumor cells can restore GJIC, growth control and reduce tumorigenicity (Na et al. 
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2000). Previous studies from Trosko and Chang clearly suggest that dietary factors can modulate 
GJIC by inducing various signal transducing systems (Trosko and Chang 2001). The modulation 
can either down-regulate GJIC leading to tumor promotion or it can up-regulate GJIC and lead to 
suppression of the initiated cells. Hence, increasing gap junction activity or enhancing GJIC in 
tumor cells provides the means to enhance anti-neoplastic therapies. The goal of our studies is to 
examine PQs that specifically activate GJIC activity and inhibit cancer cell growth. The results 
demonstrated that these small molecules may be the potential combinational therapeutic drugs 
for breast cancer. 
 
4.3 Materials and Methods 
 
4.3.1 Cell line and cell culture 
T47D human breast cancer cell line was purchased from American Type Culture 
Collection (Manassas, VA). Cells were grown in RPMI medium supplemented with 10% fetal 
bovine serum (Atlanta Biologicals, Lawrenceville, GA), 10% antibiotic-actinomycotic at 37°C 
with 5% CO2 in 75cm2 flasks. 
 
4.3.2 Western Blot Analysis  
  Cells were grown in serum supplemented RPMI media until they were 90% confluent in 
75 cm2 flasks. Cells were kept in starving media containing phenol red-free DMEM with 5% 
charcoal dextran stripped serum, overnight. Cells were dosed with 0, 10, 100, 200 and 500 nM of 
PQ1 for 24 hr. Cells were washed three times with cold PBS and then were harvested using lysis 
buffer (20 mM Tris pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton X-100) with 1:1000 
dilution of protease inhibitors (Sigma-Aldrich, Saint Louis, MO). Cell lysate was sonicated and 
centrifuged at 13,000 rpm for 30 min at 4ºC. Twenty-five µg of whole cell extract was resolved 
by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose 
membrane (Midwest Scientific, Saint Louis, MO). Nitrocellulose membrane was blocked in 5% 
milk for 1 hr at room temperature and then incubated with monoclonal mouse PKC α, 1:500 
(Santa Cruz Biotechnologies, Santa Cruz, CA), mouse Cx43, 1:500 (Fred Hutchinson, Seattle, 
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Washington), rabbit actin, 1:1,000 (Sigma-Aldrich, Saint Louis, MO). Western blots were 
detected by enhanced chemiluminescence detection reagents (Pierce, Rockford, Illinois, USA).   
 
4.3.3 Gap Junction Activity 
   For scrape load/ dye transfer (SL/DT) assay, cells were grown to 90% confluency on 
cover slips, dosed with 10, 100, 200 and 500 nM of PQ 1 for 40 min. After that cells were 
washed three times with PBS. The 2.5 µl of 1% (w/v) Lucifer yellow and 0.75% (w/v) of 
Rhodamine dextran was mixed and added in the center of the coverslip. Two cuts crossing each 
other in the center of the coverslip were made. After 3 min, cells were washed three times with 
PBS and incubated at 37°C in tissue culture media for additional 20 min. The cells were then 
washed with PBS three times and fixed in 2.5% paraformaldehyde for 10 min. Cells were 
mounted on a slide, sealed and visualized under a fluorescence microscope at 10X objective.  
 
4.3.4 Measurement of transepithelial electrical resistance 
  Cells were grown to 100% confluency on a 12-well transwell (BD Biosciences, San Jose, 
CA) and treated with 0, 100, 200, and 500 nM PQ1 for 48 hr. Transepithelial electrical resistance 
(TEER) of the T47D monolayers was measured by a high-precision. Resulting voltages were 
recorded with the aid of a differential amplifier with a high input resistance. Data were corrected 
for well area (given in Ω• cm2).  
 
4.3.5 Colony Growth Using Soft Agar 
   Cells were treated with 0, 10, 100, 200 and 500 nM PQ1 for 7 days. Base agar plates 
were prepared containing 0.8% agar and 0.4% agar in Ham’s F12. Cells (5 × 104 cells/33 mm2 
well) were suspended in 100 µl of Ham’s F12 with 0.4% agar and plated. These plates were 
maintained at 37°C for 7 days and examined for the presence of colonies. Individual colonies of 
50 µm or greater were examined.   
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4.3.6 MTT assay 
   MTT (3-(4, 5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was 
performed with adherent cell cultures in a 96-well plate dosed with 0, 10, 100, 200, and 500 nM 
PQ 1 for 24 hr. Solution containing MTT was metabolized by the cells (incubation period 1 ½ 
hr). MTT is a tetrazolium salt (yellowish) cleaved to formazan crystals by succinate 
dehydrogenase enzyme, active in viable cells. The more viable cells in a well, the more formazan 
dye will be produced. After solubilization of the MTT crystals with the 0.35 N HCl 
solubilization solution, the amount of dye will be measured spectrophotometrically at 540 nm.  
 
4.3.7 General Methods for Organic Synthesis- Dr Hua’s Lab 
 NMR spectra were obtained at 400 MHz for 1H and 100 MHz for 13C in CDCl3, and 
reported in ppm. High-resolution mass spectra were obtained from ESI spectrometers. ESI 
spectra were acquired on a LCT Premier (Waters Corp., Milford, MA) time of flight mass 
spectrometer. Satisfactory 1H and 13C NMR spectra and high-resolution mass spectra of 
compounds PQ1, PQ2, PQ3, PQ4, PQ5, and 10 were obtained. Compounds PQ2–PQ5 have been 
reported in the literature (LaMontagne et al. 1982a; LaMontagne et al. 1982b; Lauer 1946).   
Compound PQ3 (LaMontagne et al. 1982b) was treated with 1 equivalent of 3-
iodopropylphthalimide (compound 9) and 1 equivalent of sodium bicarbonate in DMF at 80°C 
for 48 hr. After aqueous work-up and silica gel column chromatographic separation, a 72% yield 
(based on reacted PQ3) of compound 10 was obtained along with 77% recovery of PQ3. 
Compound 10 was heated under reflux (85°C) with an excess of hydrazine (65%) in ethanol for 3 
hours. After aqueous work-up (dilution with 10% aqueous KOH solution and extraction with 
dichloromethane) and silica gel column chromatographic separation, an 80% yield of PQ1 was 
obtained. 
 
4.3.8 Statistical analysis 
 The level of significance (see * in figure legends) was considered at p < 0.05 using 
Student's t-test analysis. All data are presented as mean ± S.D. of at least three independent 
experiments from different batches of cultures. 
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4.4 Results  
4.4.1 Synthesis of PQ1 
Intercellular communication in many organs is maintained via GJIC. Several GJIC 
enhancers have been reported; however, an effective clinical drug targeting gap junction is not 
available at this time. Our goal was to collaborate with Dr. Hua to synthesize small molecules 
that specifically activate GJIC activity and inhibit cancer cell growth. Dr. Hua’s lab designed 
novel substituted quinolines using computational docking studies, and demonstrated their 
enhancement of GJs activities and growth inhibitory effect on human breast cancer cells. The 
structures of substituted quinolines are shown in Figure 4.1 and the syntheses of PQs are 
described in Materials and Methods. PQ1 is predicted to have a high binding affinity for 
connexin via computational docking.  
 
 
 
 
Figure 4.1  Syntheses of PQ analogs.   
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PQs were synthesized via a modified procedure from 4-acetaminoanisole (compound 6). Results 
of the isolation of PQ1 are described in Materials and Methods. 
 
4.4.2 Effect of PQ1 on GJIC 
 
We tested the efficacy of compounds PQ1-PQ5 on GJIC by parachute assay in different 
cell lines – MDA-453, MCF-7, ZR75, MDA-231, and T47D cells (Appendix A.2, Figures S2-
S7). We found a significant increase in GJIC by PQ1 in T47D cells. Therefore, we chose to study 
the efficacy of PQ1 in T47D cells. We further tested the effect of PQ1 on the GJIC activity by 
another dye transfer method, SL/DT in T47D breast cancer cells. The results demonstrated that 
100, 200 and 500 nM of PQ1 show a significant increase in gap junction activity in T47D cells 
compared to controls, without PQ1 treatment and succinic acid, using scrape load/dye transfer 
assay (Figure 4.2A, top panel). Conversely, PQ1 has no effect on GJIC activity of human 
primary epithelial cells (HMEC, normal cells) compared to its controls (Figure 4.2A, bottom 
panel). The distance of dye transfer from section cut to the farthest cells with dye was measured. 
A graphical representation of three experiments indicates that 200 nM PQ1 causes an 8.5-fold 
increase in distance of dye transfer compared to control (Figure 4.2B). HMECs have uniform 
uptake of Lucifer yellow. This is due to the existing high level of gap junction activity in these 
normal cells.   
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Figure 4.2  Gap Junction Activity.  
A) T47D (Top panel), and A) HMEC cells (Bottom panel) were treated with 0, 100, 200, and 
500 nM PQ1 for 1 hr. Controls are media alone and succinic acid. Scrape load/dye transfer assay 
was performed as described in Materials and Methods. White dash lines indicate a cross section 
cut of initial dye. Lucifer yellow was used as a gap junctional dye and rhodamine-dextran was 
used to mark the cutting site. Fluorescence green indicates the passages of dye from the cutting 
site, showing increase of GJIC. B) Graphical presentation of three experiments shows the 
distance of dye transfer of T47D cells.   
 
4.4.3 Effect of PQ1 on tight junctions, colony growth assay and cell viability 
Furthermore, 100, 200, or 500 nM of PQ1 has no significant effect on tight junction ion 
permeability by using transepithelial electric resistance (TEER) compared to control (Figure 
4.3). This suggests that PQ1 enhances only affected gap junctional activity without having an 
effect on tight junction. These results demonstrated that PQ1 is sufficient to cause an increase in 
GJIC activity in SL/DT assay.   
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Figure 4.3  Effect of PQ1 on transepithelial electrical resistance (TEER).   
T47D cells were treated with 0, 100, 200, and 500 nM PQ1 for 48 hr. TEER assay was 
performed as described in Materials and Methods. TEER values of each treatment in KΩ/cm2 
were converted to relative percent of control.  
 
Various oncogenes (e.g. ras, raf, neu, src, mos) down-regulate GJIC while several tumor 
suppressor genes can up-regulate GJIC. Thus, we examined the effect of PQ1-upregulated gap 
junction activity in T47D colony growth formation. Cells were grown in soft agar to assess their 
capacity for anchorage-independent growth, which is a key feature of cell transformation. HMEC 
and T47D cells were treated with 10, 100, 1000, and 10,000 nM PQ1 for 7 days. A graphical 
presentation of three experiment results is presented in log scale of PQ1 concentration. The 
effect of PQ1 on T47D cells showed a significant inhibition of T47D cell colony growth 
compared to control (Figure 4.4). A 100 nM PQ1 inhibits 66% of colony growth compared to 
controls, without PQ1 treatment or 100 nM succinic acid. Interestingly, the same concentration 
(100 nM PQ1) has no effect on HMECs (data not shown). This suggests that 100 nM PQ1 can 
cause an increase in GJIC activity and subsequently can decrease colony growth of T47D cells.  
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Figure 4.4  Effect of Substituted Quinolines on T47D Cells.   
Base agar plates were prepared containing 0.8% agar and 0.4% agar in Ham’s F12. Cells (5 × 104 
cells/33 mm2 well) were suspended in 100 µl of Ham’s F12 with 0.4% agar and plated. These 
plates were maintained at 37°C for 7 days and examined for the presence of colonies. Individual 
colonies of 50 µm or greater were examined. T47D cells were treated with 1, 10 and 100 nM 
PQ1 and SA (succinic acid) as a solvent control. Individual colonies of 50 µm or greater were 
examined. Statistical significance, *p<0.05, of at least three experiments. 
 
We also determined the cytotoxicity of PQ1 in HMEC and T47D cells using MTT assay. 
Cells were treated with 10, 100, 200, 500, 1000 nM PQ1 for 24 hr. MTT assay was performed 
according to the manufacturer’s recommendations. A 200 nM PQ1 has 67% cell viability 
compared to controls (Figure 4.5). 1 µM PQ1 can further decrease cell viability to 50% in T47D 
cells. However, treatments of 100 and 200 nM PQ1 have 95% and 103% HMEC cell viability 
compared to control (data not shown). Thus, PQ1 has no cytotoxic effect to HMECs. 
 
87 
 
                        
 
Figure 4.5  Effect of PQ1 on Cell Viability.   
T47D breast cancer cells were treated with various concentrations of PQ1 for 24 hr. MTT assay 
was performed with adherent cell cultures using a culture medium free of phenol red and of 
serum. Solution containing MTT was metabolized by the cells (incubation period 3 hr). After 
solubilization of the MTT crystals with the solubilization solution MTT, the amount of dye was 
measured spectrophotometrically at 570 nm. 
 
4.4.4 Effect of PQ1 on the expression of different connexins 
Furthermore, whole cell extract of PQ1 treatment was analyzed for the changes in gap 
junctional proteins, connexins. Cells were treated with 10, 100, 200, and 500 nM PQ1 for 24 hr. 
Western blot analysis was performed against Cx26, Cx32, and Cx43 (Figure 4.6). The results 
show that PQ1 has no effect on Cx26, Cx32, and Cx43 expression. Interestingly, a decrease in 
phosphorylated Cx43 was observed in 500 nM PQ1 treatment of T47D cells. Anti-tubulin was 
used as a loading control. These results suggest that PQ1 does not affect the expression of 
connexins but directly causes a decrease in phosphorylation of connexin.  
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Figure 4.6  Effect of PQ1 on the expression of different connexins in T47D cells.  
T47D cells were dosed with PQ1 for 24 hr. The Western blot analysis was performed as 
described in Materials and Methods. Whole cell extract was analysed for Cx43, Cx32, and Cx26.  
Experiment was performed at least three times.   
 
4.4.5 PQ1 causing apoptosis 
Mitochondrial damage in treatment of PQ1 was observed using electron microscopy (data 
not shown), suggesting that these cells are under stress and apoptotic conditions. We further 
examined the effect of PQ1 on apoptosis by detecting the active form of caspase 3. T47D cells 
were treated with 100, 500, and 1000 nM PQ1 for 24 hr. Western blot analysis was performed 
using active form of caspase 3 antibodies. A 200 nM PQ1 causes 1.5-fold increase of active 
caspase 3 compared to control (Figure 4.7). However, a decrease of caspase is observed at higher 
concentrations, a common effect in apoptotic protein expression. This is due to the cytotoxic 
response of the cells. A small pilot study was conducted to study the effect of PQ1 on T47D 
xenograft tumor growth in nude mice. However, statistical significance was not achieved as only 
three animals per group (control, PQ1-treated, and tamoxifen-treated) were included in the study. 
(A2, S 8-12) 
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Figure 4.7  Effect of PQ1 on Active Caspase 3.   
T47D cells were treated with 0, 200 nM, 500 nM and 1 µM PQ1 for 24 hr. Treatment with 
succinic acid was used as control. Western blot analysis was performed. Nitrocellulose 
membrane was blotted with the active form of caspase 3 antibodies (16 KDa). Actin acts as 
loading control. Graphical presentation of three experiments are presented with statistical 
significance, p<0.05. 
 
4.5 Conclusions  
Since an effective clinical drug targeting gap junction is not available presently, Dr. Hua 
used computational docking method to search for chemicals that bind to connexon. After 
screening several classes of molecules, substituted quinolines were focused on based on their 
relative binding constants and bioactivities. Quinolines are known for their anti-malarial 
[Wiesner 2003], antibacterial (Veyssier 2005) and anticancer (Boyle 2006; Cnubben 2005; 
Kawase 2003; Levitt 1999) activities. Recently, quinolines were examined in ATP-binding 
cassette drug transporter inhibition (Cnubben 2005), targeting tumor hypoxia (Boyle 2006), 
modulation of multidrug resistance (Kawase 2003), and tyrosine kinase inhibition (Levitt 1999). 
Beside activation of GJIC, quinolines may provide additional beneficial effects. 
Over forty years, the loss of GJIC has been described in cancer cells and led to a 
hypothesis that defects in GJIC is involved in the carcinogenesis process (Loewenstein and 
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Kanno 1966). Numerous reports have been confirmed that gap junctions are frequently decreased 
or absent in cancer cells. Co-culture of tumor cells with normal cells, or with connexin-
overexpressing cells, results in growth retardation of neoplastic component by the establishment 
of functional communication as observed with dye transfer (Zhu et al. 1992). This retardation of 
tumor growth could be prevented by co-culturing transformed cells with junctional competent 
normal cells transfected with a connexin-specific antisense reagent (Goldberg et al. 1994). Thus, 
these results indicate that signals from adjacent normal cells can reverse a malignant phenotype 
and that their failure to accomplish this is due to a lack of GJIC.   
The relationship between cell communication and cell growth has been established that 
the capability of cells to communicate through gap junction is negatively related to their growth 
activity. We have demonstrated that increased GJIC activity in T47D cells can cause a decrease 
in cell growth (Figures 4.2 and 4.3). These results were also observed by Saez et al. (Saez et al. 
2003) that an increase in GJIC is directly related to the anti-tumor effect in human mammary 
cancer cell line. Interestingly, PQ1 only affects T47D breast cancer cells and not normal 
mammary epithelial cells. In normal tissues, gap junctions are active and well-regulated between 
the cytoplasm of contacting cells (Loewenstein 1979; Loewenstein 1981; Yamasaki and Naus 
1996). Through the passage of signaling molecules, GJIC contributes to the regulation of cell 
proliferation, differentiation, cell death, and homeostatic maintenance. Numerous studies clearly 
show that altered GJIC is involved in cell cycle progression. In most cell types, GJIC is reduced 
in the late G1, S and M phases (Ruch 1994). The specific cell cycle state in which GJIC and/or 
connexin expression are modified, however, depends on both the cell type and the nature of the 
connexin species being investigated. We found that PQ1 has no effect on connexin expression; 
however, it causes a decrease in phosphorylation of connexin (Figure 4.6). Upregulation of GJIC 
activity is dependent on the unphosphorylated connexins. Thus the observation is consistent with 
the increase of GJIC activity (Figure 4.2) and a decrease of phosphorylation of Cx43 (Figure 
4.6). 
In summary, PQ1 specifically enhances GJIC activity and does not affect the 
transepithelial electrical resistance of T47D cells. An increase of PQ1-induced GJIC activity 
causes a significant decrease of colony cell growth; however, PQ1 has no effect on primary 
mammary epithelial cells. Since normal epithelial cells have well-regulated gap junction 
channels, the change of GJIC activity in these cells was not observed. The decrease of cell 
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viability and colony cell growth is subsequently of PQ1-induced apoptosis as the result of 
upregulation of active caspase 3. Thus, PQ1 is the first known compound to enhance GJIC 
activity in T47D breast cancer cells. 
 
Acknowledgements 
We gratefully acknowledge financial support from the National Institutes of Health 
(COBRE-R20RR017686, K-INBRE-P20RR016475, and National Institute of Aging- 
R01AG025500), National Science Foundation (CHE-0555341 and NSF43529), American Heart 
Association, Heartland Affiliate (0750115Z), and Kansas State University-Center for Basic 
Cancer Research. 
 
92 
 
 
4.6 References  
 
Acevedo P, Bertram JS. (1995). Liarozole potentiates the cancer chemopreventive activity of and 
the up-regulation of gap junctional communication and connexin43 expression by 
retinoic acid and beta-carotene in 10T1/2 cells. Carcinogenesis 16 (9), 2215-22. 
Ammerpohl O, Thormeyer D, Khan Z, Appelskog IB, Gojkovic Z, Almqvist PM, Ekstrom TJ. 
(2004). HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma 
cells. Biochem Biophys Res Commun 324 (1), 8-14. 
Bhimani RS, Troll W, Grunberger D, Frenkel K. (1993). Inhibition of oxidative stress in HeLa 
cells by chemopreventive agents. Cancer Res 53 (19), 4528-33. 
Boyle RG, Travers, S. (2006). Hypoxia: targeting the tumor. Anti-cancer Agents in Med. Chem. 
6, 281-286. 
Bruzzone R, White TW, Paul DL. (1996). Connections with connexins: the molecular basis of 
direct intercellular signaling. Eur J Biochem 238 (1), 1-27. 
Clark PE, Hall MC, Borden LS, Jr., Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Jr., 
Lovato J, Harmon M and others. (2006). Phase I-II prospective dose-escalating trial of 
lycopene in patients with biochemical relapse of prostate cancer after definitive local 
therapy. Urology 67(6),1257-61. 
Cnubben NHP, Wortelboer, H. M., van Zanden, J. J., Rietjens, V. M. C. M., van Bladeren, P. J. 
(2005). Metabolism of ATP-binding cassette drug transporter inhibitors: complicating 
factor for multidrug resistance. Expert Opinion on Drug Metabol. & Toxicol. 1, 219-232. 
Dubina MV, Iatckii NA, Popov DE, Vasil'ev SV, Krutovskikh VA. (2002). Connexin 43, but not 
connexin 32, is mutated at advanced stages of human sporadic colon cancer. Oncogene 
21(32), 4992-6. 
Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC. (1991). Involvement of gap junctions in 
tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in 
vivo. Proc Natl Acad Sci 88(23), 10701-5. 
Fleishman SJ, Unger VM, Ben-Tal N. (2006). Transmembrane protein structures without X-rays. 
Trends Biochem Sci 31(2), 106-13. 
Foote CI, Zhou L, Zhu X, Nicholson BJ. (1998). The pattern of disulfide linkages in the 
extracellular loop regions of connexin 32 suggests a model for the docking interface of 
gap junctions. J Cell Biol 140 (5), 1187-97. 
Goldberg GS, Martyn KD, Lau AF. (1994). A connexin 43 antisense vector reduces the ability of 
normal cells to inhibit the foci formation of transformed cells. Mol Carcinog 11 (2), 106-
14. 
Goodsell DS, Olson AJ. (1990). Automated docking of substrates to proteins by simulated 
annealing. Proteins 8 (3), 195-202. 
93 
 
Holder JW, Elmore E, Barrett JC. (1993). Gap junction function and cancer. Cancer Res 53 (15), 
3475-85. 
Huang RP, Hossain MZ, Huang R, Gano J, Fan Y, Boynton AL. (2001). Connexin 43 (cx43) 
enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 92 
(1), 130-8. 
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancer statistics, 2007. CA 
Cancer J Clin 57 (1), 43-66. 
Kawase M, Motohashi, N. (2003). New multidrug resistance reversal agents. Curr. Drug Targets 
4, 31-43. 
LaMontagne MP, Blumbergs P, Strube RE. (1982a). Antimalarials. 14. 5-(aryloxy)-4-
methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal 
agents. J Med Chem 25 (9), 1094-7. 
LaMontagne MP, Markovac A, Khan MS. (1982b). Antimalarials. 13. 5-Alkoxy analogues of 4-
methylprimaquine. J Med Chem 25 (8), 964-8. 
Lauer WMR, C.; Arnold, R. T.; Drake, N. L.; Hook, J. V.; Tinker, J. .(1946). Some derivatives 
of 8-aminoquinoline. J. Am. Chem. Soc. 68, 1546-1548. 
Levitt ML, Koty, P. P. (1999). Tyrosine kinase inhibitors in preclinical development. . Invest. 
New Drugs 17, 213-226. 
Livny O, Kaplan I, Reifen R, Polak-Charcon S, Madar Z, Schwartz B. (2002). Lycopene inhibits 
proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. 
J Nutr 132 (12), 3754-9. 
Loewenstein WR. (1979). Junctional intercellular communication and the control of growth. 
Biochim Biophys Acta 560 (1), 1-65. 
Loewenstein WR. (1981). Junctional intercellular communication: the cell-to-cell membrane 
channel. Physiol Rev 61 (4), 829-913. 
Loewenstein WR, Kanno Y. (1966). Intercellular communication and the control of tissue 
growth: lack of communication between cancer cells. Nature 209 (5029), 1248-9. 
Makowski L, Caspar DL, Phillips WC, Goodenough DA. (1977). Gap junction structures. II. 
Analysis of the x-ray diffraction data. J Cell Biol 74 (2), 629-45. 
Martin PE, Evans WH. (2004). Incorporation of connexins into plasma membranes and gap 
junctions. Cardiovasc Res 62 (2), 378-87. 
Morris GM, Goodsell DS, Huey R, Olson AJ. (1996). Distributed automated docking of flexible 
ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10 
(4), 293-304. 
Morris GM, Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J. 
(1998). Automated docking using Lamarckian genetic algorithm and an empirical 
binding free energy function. .J. Comp. Chem. 19, 1639-1662. 
94 
 
Musil LS, Le AC, VanSlyke JK, Roberts LM. (2000). Regulation of connexin degradation as a 
mechanism to increase gap junction assembly and function. J Biol Chem 275 (33), 
25207-15. 
Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D, Trosko JE. (2000). Restoration of gap 
junctional intercellular communication by caffeic acid phenethyl ester (CAPE) in a ras-
transformed rat liver epithelial cell line. Cancer Lett 157 (1), 31-8. 
O'Byrne KJ, Han C, Mitchell K, Lane D, Carmichael J, Harris AL, Talbot DC. (1998). Phase II 
study of liarozole in advanced non-small cell lung cancer. Eur J Cancer 34 (9), 1463-6. 
Ruch RJ. (1994). The role of gap junctional intercellular communication in neoplasia. Ann Clin 
Lab Sci 24 (3), 216-31. 
Ruch RJ, Madhukar BV, Trosko JE, Klaunig JE. (1993). Reversal of ras-induced inhibition of 
gap-junctional intercellular communication, transformation, and tumorigenesis by 
lovastatin. Mol Carcinog 7 (1), 50-9. 
Saez CG, Velasquez L, Montoya M, Eugenin E, Alvarez MG. (2003). Increased gap junctional 
intercellular communication is directly related to the anti-tumor effect of all-trans-retinoic 
acid plus tamoxifen in a human mammary cancer cell line. J Cell Biochem 89 (3), 450-
61. 
Trosko JE, Chang CC. (2001). Mechanism of up-regulated gap junctional intercellular 
communication during chemoprevention and chemotherapy of cancer. Mutat Res 480-
481:219-29. 
Trosko JE, Chang CC, Madhukar BV, Klaunig JE. (1990). Chemical, oncogene and growth 
factor inhibition gap junctional intercellular communication: an integrative hypothesis of 
carcinogenesis. Pathobiology 58 (5), 265-78. 
Unger VM, Kumar NM, Gilula NB, Yeager M. (1999). Three-dimensional structure of a 
recombinant gap junction membrane channel. Science 283 (5405), 1176-80. 
Veenstra RD. (2003). Gap junction channel structure. Recent Res. Devel. Biophys. 2, 65-94. 
Veyssier P, Bryskier, A. (2005). Dihydrofolate reductase inhibitors, nitroheterocycles (furans) 
and 8-hydroxyquinolines. Internal Medicine, Hospital de Compiegne, Bryskier, A. 
Ed.,Compiegne, Fr. P .941-963. 
Wei N, Mi MT, Zhou Y. (2007). Influences of lovastatin on membrane ion flow and intracellular 
signaling in breast cancer cells. Cell Mol Biol Lett 12 (1), 1-15. 
Wiesner J, Ortmann, R., Jomaa, H., Schlitzer, M. (2003). New antimalarial drugs. . Angew. 
Chem. Int. Ed. (42), 5274-5293. 
Wilgenbus KK, Kirkpatrick CJ, Knuechel R, Willecke K, Traub O. (1992). Expression of Cx26, 
Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J 
Cancer 51(4), 522-9. 
Yamasaki H, Naus CC. (1996). Role of connexin genes in growth control. Carcinogenesis 17(6), 
1199-213. 
95 
 
Zhang ZQ, Lin ZX, Lu YY. (1994). Studies on the reduction of malignant phenotypes in a highly 
metastatic human lung carcinoma-correlated changes of intercellular communication, 
cytoskeletons, oncogenes and antioncogene. Cancer Res 16(2), 88-92. 
Zhu D, Kidder GM, Caveney S, Naus CC. (1992). Growth retardation in glioma cells cocultured 
with cells overexpressing a gap junction protein. Proc Natl Acad Sci 89 (21), 10218-21. 
 
 
96 
 
 
Chapter 5 -  Combinational treatment of PQ1 and tamoxifen 
induces increased apoptosis in T47D breast cancer cells 
5.1 Abstract  
Tamoxifen is a drug of choice for endocrine-responsive breast tumor patients. However, 
tamoxifen resistance has become a major concern for the treatment of breast cancer. 
Combinational therapies of tamoxifen and different drugs are being frequently studied. In the 
current study, we tested the efficacy of PQ1 (code name) in combination with tamoxifen in T47D 
cells. Colony growth assay was performed using soft agar to measure the colony growth while 
cell proliferation was measured by MTT assay in T47D cells. Confocal microscopy was used to 
measure Ki67, survivin and BAX expression along with western blot. APO-BrdU labeling 
indicated the apoptosis induced by the treatment in T47D cells. We observed a 55% decrease in 
the colony growth in the presence of combination of PQ1 and tamoxifen; while tamoxifen alone 
has little effects. Combination of 10 µM tamoxifen and PQ1 200 nM or 500 nM resulted in only 
16% cell viability compared to controls at 48 hr in T47D cells by MTT assay. We found a 
significant increase in BAX protein at 1 hr in the presence of 500 nM PQ1 alone, 10 µM 
tamoxifen alone and combination of PQ1 and tamoxifen. A 2-fold increase was observed in 
active caspase 3 in the presence of combinational treatment of 10 µM tamoxifen and 200 or 500 
nM PQ1. Also, flow cytometric analysis showed a 50% increase in the number of apoptotic cells 
in the presence of combination of tamoxifen and PQ1 compared to the control.  Furthermore, the 
results show that the expression of survivin is not affected by PQ1 (200 or 500 nM) whereas 
tamoxifen alone or in combination with PQ1 significantly reduces survival of T47D cells. We 
observed a significant increase in BAX expression, caspase 3 activation and DNA fragmentation 
in combinational treatment of tamoxifen and PQ1 as compared to their individual treatments.  
Tamoxifen alone and combination with PQ1 showed a decrease in the survivin expression while 
PQ1 alone shows to be independent of survivin-mediated pathway. The combinational treatment 
of tamoxifen and PQ1 showed a significant decrease in cell viability compared to tamoxifen 
treatment alone. The present study demonstrates for the first time that combinational treatment of 
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tamoxifen and PQ1 (gap junctional activator) can be used to potentiate apoptosis of T47D human 
breast cancer cells. This could alter either the length or dose of tamoxifen clinically used for 
breast cancer patients. 
 
5.2 Introduction  
Tamoxifen is one of the most commonly and successfully used chemotherapeutic agent 
for the treatment of endocrine responsive breast cancers (Clarke et al., 2001). Tamoxifen is 
better known as a selective estrogen receptor modulator (SERM) because of its multiple 
activities (Osborne, 1998). Clinical experience with this drug likely now exceeds 10 million 
patient years. Unfortunately, in most patients, cancers that initially respond to tamoxifen 
gradually acquire resistance to the treatment and require alternative systemic therapies (Berstein 
et al., 2003). Despite extensive experience with this drug, the precise mechanisms that confer 
resistance remain unknown. A number of mechanisms have been proposed to control 
antiestrogen resistance in ER+ breast cancer (Riggins et al., 2007), but many details of these 
mechanisms continue to be unclear (Riggins et al., 2008). These include changes in the host 
immunity, host endocrinology, or antiestrogen pharmacokinetics (Clarke et al., 2001). Under 
host endocrinology, some tumors spontaneously become hormone-independent despite the 
presence of estrogen receptors; in others, tumors that are initially ER + become ER- over time 
(Hull et al., 1983; Encarnacion et al., 1993). Numerous trials have been conducted using the 
combinational treatment of chemotherapy plus tamoxifen but the results have been controversial 
(Mouridsen et al., 1988; Goldhirsch A, 1989; Fisher et al., 1990; Rivkin et al., 1994; group, 
1997; Pritchard et al., 1997).  
Gap junctions are the intercellular plasma membrane channels which allow the passage of 
small molecules from one cell to other. The flux of molecules through the channels is called the 
gap junctional intercellular communication (GJIC) (Vinken et al., 2006). GJIC exists in most of 
the mammalian cells and is involved in cell growth, differentiation, and homeostasis. Since 
decades it has been shown that the mitotic cells in the cell cycle show decreased GJIC (PO 
Lague, 1970; Goodall and Maro, 1986; Stein et al., 1992). Therefore, it leads to a state that the 
cell-cell communication is negatively related to the capability of the cell to grow. Due to its 
effect on the cell growth, many studies were conducted to find a co-relation between the GJIC 
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and cancer. Many in vitro studies showed that tumor-promoting agents lead to a decrease in 
GJIC (Murray and Fitzgerald, 1979; Yotti et al., 1979; Enomoto et al., 1981; Trosko, 1983) 
while in vivo studies supported the in vitro data (Sugie et al., 1987; Mesnil et al., 1988). Protein 
and mRNA analysis showed a decrease in connexin expression in preneoplastic lesions as well as 
hepatocellular carcinomas (Fitzgerald et al., 1989; Neveu MJ, 1989).  
In our previous study we found a gap junctional activator, substituted quinolines (PQ1). 
We showed that PQ1 (200 nM) showed a 30% increase in the GJIC in T47D cells; however, 
there was no effect of PQ1 treatment on GJIC in normal mammary epithelial cells. In addition to 
an increase in GJIC, 80-95% growth attenuation was observed by PQ1 in colony growth assay. 
Moreover, an increase in caspase 3 with PQ-treated cells was observed, suggesting a possible 
involvement in apoptosis ( Gakhar et al., 2008).  
The antitumor effects of tamoxifen are thought to be due to its antiestrogenic activity, 
mediated by competitive inhibition of estrogen binding to estrogen receptors (Osborne, 1996). 
The inhibition of expression of estrogen-regulated genes causes decrease in cell growth and 
proliferation (Langan Fahey SM, 1994). Tamoxifen may also directly affect the programmed-cell 
death (Ellis et al., 1997). Our previous studies conducted on PQ1 have also shown an increase in 
caspase-3 and a decrease in breast tumor growth. Therefore, we examined the effect of 
combinational treatment of tamoxifen and the gap junctional activator, PQ1 on breast cancer 
cells. In the present study, we found an increase in T47D human breast cancer cell death 
observed by different mechanisms in the presence of combinational therapy of PQ1 and 
tamoxifen. A significant increase in BAX and caspase 3 followed by an increased apoptosis by 
APO-BrdU incorporation at different dosing time in the presence of both tamoxifen and PQ1 was 
observed. Furthermore, a decrease in the colony growth, MTT assay and an increased DNA 
fragmentation were observed in the combinational treatment of PQ1 and tamoxifen. 
 
5.3 Materials and Methods 
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5.3.1 Cell Lines and Culture 
 The T47D human breast cancer cell line was purchased from American Type Cell 
Culture (ATCC, Manassas, VA). Cells were grown in RPMI medium supplemented with 10% 
fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 10% antibiotic-antimycotic at 37°C 
with 5% CO2 in 75 cm2 flasks. Tamoxifen citrate was purchased from Sigma (Saint Louis, MO). 
 
5.3.2 Cell Morphology 
 Cells (5,000 cells/ml) were seeded in a 6-well plate and dosed with 200 nM PQ1 alone, 
10 µM tamoxifen alone, combination of tamoxifen and PQ1, and combination of tamoxifen and 
estrogen (10 nM) for 24, 48 and 72 hr. Cells were observed under a microscope at 40X objective.  
 
5.3.3 Colony Growth Using Soft Agar Assay 
Cells were treated with ethanol, 200 nM PQ1, 10 µM tamoxifen, and combination of 200 
nM PQ1 and 10 µM tamoxifen for 7 days. Base agar plates were prepared containing 0.8% agar 
and 0.4% agar in RPMI. Cells (5 × 104 cells/33 mm2 well) were suspended in 100 µl of RPMI 
with 0.4% agar and plated. These plates were maintained at 37°C for 7 days and examined for 
the presence of colonies. Individual colonies of 50 µm or greater were examined. 
 
5.3.4 MTT Assay 
The MTT [3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was 
performed with cell cultures in a 96-well plate incubated with 200 and 500 nM PQ1, 10 µM 
tamoxifen alone, and combination of 10 µM tamoxifen and 200 or 500 nM PQ1 for 1, 48 and 72 
hr. The MTT solution was metabolized by the cells (incubation period 1 hr) at 37°C. MTT is a 
tetrazolium salt (yellowish) cleaved to formazan crystals by succinate dehydrogenase. In viable 
cells, more formazan dye will be produced. After solubilization of MTT crystals with the 0.35 N 
HCl solubilization solution, dye was measured spectrophotometrically at 570 nm with the 
background subtraction at 650 nm. 
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5.3.5 Western Blot Analysis 
Cells were grown in serum-supplemented RPMI media until they were 90% confluent in 
25-cm2 flasks. Cells were incubated with PQ1 alone, 10 µM tamoxifen alone, and combination 
of tamoxifen and PQ1 for 1, 48 and 72 hr. Cells were washed 3 times with cold PBS and 
harvested using cell lysis buffer (20 mM Tris pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% 
Triton X-100) with 1:1,000 dilution of protease inhibitors (Sigma-Aldrich, St. Louis, MO) for 10 
min followed by rotation on a shaker for 30 min at 4°C. Cells were vortexed and centrifuged at 
13,000 rpm for 30 min at 4°C. Forty µg of whole cell extract was resolved by 10% SDS-
polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membrane 
(Midwest Scientific, St. Louis, MO). Nitrocellulose membrane was blocked in 5% milk for 1 hr 
at room temperature and incubated with polyclonal rabbit Bcl2, (1:200), mouse BAX (1:200, 
Santa Cruz Biotechnologies, Santa Cruz, CA), polyclonal rabbit caspase 3 (1:500, BD 
Pharmingen, San Diego, CA), polyclonal rabbit survivin (1:1,000, Novus Biologicals, CO, USA) 
and  polyclonal rabbit actin (1:1,000, Sigma-Aldrich, Saint Louis, MO). Western blots were 
detected by enhanced chemiluminescence (ECL) detection (Amersham, Pittsburg, PA). 
 
5.3.6 Immunofluorescence and Confocal Microscopy 
Cells were grown on coverslips in 6-well plates in RPMI media. Cells were treated with 
PQ1 alone, tamoxifen alone, and combination of tamoxifen and PQ1 for 1, 48 and 72 hr. Cells 
were fixed with 2% paraformaldehyde for 20 min and then neutralized with 50 mM glycine for 5 
min. The cells were lysed with 0.1% Triton X-100 for additional 10 min. After washing with 
PBS, cells were blocked with 2.5% BSA in PBS for 2 hr and then incubated with primary 
antibodies,  rabbit Ki67 (1:250, Santa Cruz Biotechnologies, Santa Cruz, CA) and  mouse BAX 
(1: 50, Santa Cruz, CA), rabbit survivin (1:250, Novus Biologicals, CO, USA) for 15 hr at 4°C. 
Following this step, cells were incubated in DAPI for a minute and then incubated with anti-
mouse and anti-rabbit Alexa fluor 488 and 568 (Molecular probes, Eugene, OR, USA) for 4 hr at 
4°C, respectively. Cells were analyzed for nuclear morphology by staining with DAPI. Samples 
were sealed and analyzed by a confocal microscope (Carl Zeiss LSM 510 META, Narashige, 
MN). 
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5.3.7 Apoptosis Assay by Flow Cytometry 
Cells were grown in a 35 mm2 dish and then dosed with PQ1 alone, tamoxifen alone, and 
combination of tamoxifen and PQ1 for 1, 48 and 72 hr. Cells were trypsinized and stained with 
APO-BrdU TUNEL Assay kit (Molecular Probes # A23210, Carlsbad, CA) according to the 
manufacturer’s protocol. APO-BrdU binding was analyzed by flow cytometry using a BD 
FACSCalibur system and the data obtained was analyzed using the CellQuest software. 
5.4 Results and Discussion  
 
5.4.1 Current  treatment with tamoxifen 
Breast cancer is the second leading cause of cancer deaths in North American women. 
Tamoxifen has been the single agent of choice in treating hormone responsive breast cancer 
cases since 1971. Even though tamoxifen has been shown to be 50% more effective than placebo 
in preventing the occurrence of breast cancer in high-risk population, the risk of developing 
uterine cancer has increased by more than 40% (Mandlekar and Kong, 2001). The line of 
treatment with tamoxifen includes the usage of the drug for at least 5 years in most of the 
patients. Long-term treatment with tamoxifen induces tamoxifen resistance; however, the 
mechanism of which is still being elucidated (Osborne, 1998). Therefore, it is necessary to 
develop effective modalities to enhance the efficacy of tamoxifen. In our present study we 
propose to observe the combinational effect of PQ1 and tamoxifen. PQ1 has been shown to be a 
gap junctional activator and induced cell death in both in vitro and in vivo treatments ( Gakhar et 
al., 2008). Tamoxifen has also shown to induce apoptotic cell death both in vitro and in vivo 
(Perry et al., 1995; Gelmann, 1996; Martin et al., 1996). This effect was concentration-
dependent. At nanomolar (nM) concentrations of tamoxifen, only growth arrest occurs whereas 
at micromolar (µM) concentrations induction of cell death was observed in cell cultures. We 
observed the effect of both PQ1 and 10 µM tamoxifen on T47D human breast cancer cell line. 
Our previous study suggested a tremendous increase in GJIC in the presence of PQ1 in T47D 
cells compared to other breast cancer cell lines (MCF7, MDA231, MDA453 and ZR75) ( Gakhar 
et al., 2008).  
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5.4.2 PQ1 and tamoxifen affects cell morphology, proliferation and colony growth in 
T47D cells 
Cell morphology was tremendously affected in the presence of 200 nM PQ1 for 24, 48 
and 72 hr in which cells were being detached from the plate. In the presence of 10 µM tamoxifen 
for 24, 48, and 72 hr, cells showed a marked change in the morphology, including shrinkage, 
irregular shape and some cells were floating in the media (Figure 5.1 A, B, C). The combination 
of PQ1 and tamoxifen showed the complete loss of structure of cells as well. Cells partially 
regained back their structure in the presence of 10 µM tamoxifen and 10 nM 17β-estradiol. 
These results suggest that the combinational treatment of tamoxifen and PQ1 can potentiate the 
effect of tamoxifen.  
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Figure 5.1  Effect of PQ1 and tamoxifen on cell morphology in T47D cells. 
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A) T47D cells were seeded in a 6-well plate for 24 hr in the presence of 200 nM PQ1, 10 µM 
tamoxifen, combination of tamoxifen and PQ1, and the combination of tamoxifen and 10 nM 
17β-estradiol (an antagonist for tamoxifen action). B) Cells were dosed for 48 hrs with the same 
treatment as above. C) T47D cells were treated with the same treatment as in (A) for 72 hr. 
Ethanol was used as a solvent control for tamoxifen at different time intervals. In the presence of 
PQ1 and tamoxifen alone and in combination, the cell structure was seen to be lost significantly 
at 48 and 72 hrs. At 10 nM 17β-estradiol and tamoxifen, a partial restoration in the cell structure 
was observed at 48 and 72 hr compared to full restoration at 24 hr. Tam=tamoxifen 
 
Colony growth assay measures the colony formation in soft agar. Soft agar is used to 
measure the anchorage-independence (feature of cancerous cells) of the cells. We observed a 
55% decrease in the colony growth in the presence of combination of PQ1 and tamoxifen (Figure 
5.2). This suggests that the combinational treatment of tamoxifen and PQ1 is sufficient to cause a 
significant decrease of colony growth at 7-day incubation compared to tamoxifen or PQ1 
treatment alone. Ethanol treatment, a solvent control, shows no effect in colony growth of T47D 
cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  Combination of 200 nM PQ1 and tamoxifen decreases the colony growth in 
T47D cells. 
Cells were dosed with 200 nM PQ1, 10 µM tamoxifen and combination of both for 7 days in a 
soft agar. After 7 days, colonies > 50 µm were counted. Combination of PQ1 and tamoxifen 
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resulted in a 55% decrease in the colony growth compared to 20% and 10% decrease in the 
presence of 200 nM PQ1 and tamoxifen alone, respectively. Graphical representation of three 
experiments with ± SD and statistical significance *p < 0.05. Note that the significance *p< 0.05 
was found in all the treatments compared to control at 48 and 72 hr. 
 
In MTT assay, 200 and 500 nM PQ1 showed a 60% and 50% cell viability at 48 hr, 
respectively (Figure 5.3). Tamoxifen (10 µM) showed 30% cell viability whereas combination of 
tamoxifen and PQ1 resulted in only 16% cell viability at 48 hr compared to controls at 48 hr in 
T47D cells. Both tamoxifen (10 µM) and PQ1 (200 and 500 nM) resulted in a decrease in cell 
growth by 50% compared to tamoxifen treatment alone at 48 hr. At 72 hr, combinational 
treatment of tamoxifen and PQ1 (200 and 500 nM) resulted in 20% and 13% cell viability, 
respectively. Thus, 48 hr is sufficient to cause a significant decrease with combinational 
treatment of tamoxifen and PQ1. Interestingly, cell viability was not affected by either 200 or 
500 nM PQ1 at 1 hr; however, tamoxifen treatment alone resulted in 28% decrease in cell 
growth. The cell viability was greatly affected by MTT assay at 48 hr compared to 72 hr in the 
presence of PQ1 alone or tamoxifen alone or their combinations. 
 
 
 
Figure 5.3  MTT assay to measure the T47D cell proliferation in the presence of tamoxifen 
and PQ1. 
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Cells were treated with 200 and 500 nM PQ1 and 10 µM tamoxifen and combination of 
tamoxifen and either 200 or 500 nM PQ1 for 1, 48 and 72 hr. At 1 hr, 50 % decrease in cell 
growth was observed in the presence of tamoxifen and 500 nM PQ1. At 48 hr, PQ1 200 and 500 
nM alone, tamoxifen alone, combination of tamoxifen and 200 nM PQ1, and combination of 
tamoxifen and 500 nM PQ1 showed a cell viability of 60, 50, 30, 16, and 16 %, respectively. At 
72 hr the combination of both tamoxifen and either PQ1 200 or 500 nM resulted in 20% and 13% 
cell viability, showing no further decrease compared to 48 hr. Graphical representation of three 
experiments with ± SD and statistical significance *p < 0.005 for 48 hr and **p < 0.05 for 72 hr . 
Note the *p values indicate the significance between the tamoxifen treatment alone or with PQ1 
combination. 
 
5.4.3 Tamoxifen and PQ1 affecting Ki67 expression 
The expression of proteins in some instances is measured in symptomatic breast cancer to 
identify the prognostic factors which are associated with the biological behavior of individual 
tumors. Ki67 is a nuclear protein widely used as a marker for cell proliferation. Tamoxifen has 
been shown to decrease the expression of Ki67 in breast cancer patients and in breast cancer cell 
lines (Clarke et al. 1993). Therefore, the effect of combinational treatment of tamoxifen and PQ1 
on Ki67 staining in T47D cells was measured. Ki67 staining was decreased in the presence of 
200 nM PQ1 at 24, 48 and 72 hr (Figure 5.4). In the presence of tamoxifen alone, no Ki67 
staining was observed at 24, 48, and 72 hr. Combinational treatment of tamoxifen and PQ1 also 
showed no Ki67 staining whereas combinational treatment of estrogen and tamoxifen showed an 
expression of Ki67 suggesting that estrogen can partially antagonize the effect of tamoxifen. 
These results suggest that PQ1 has an effect on Ki67 staining and it does not antagonize the 
effect of tamoxifen when used in combination while estrogen can reverse the effect of tamoxifen. 
Furthermore, PQ1 clearly has an effect on proliferation of T47D cells. 
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Figure 5.4  Confocal Microscopy showing the effect of PQ1 and tamoxifen on Ki67 
expression. 
Cells were treated with 200 nM PQ1, 10 µM tamoxifen, combination of 200nM PQ1 and 
tamoxifen, and combination of 10 nM 17β-estradiol for 24, 48 and 72 hr. Ethanol was used as a 
solvent control for tamoxifen. Cells treated with 200 nM PQ1, tamoxifen or combination of 
tamoxifen and PQ1 showed a tremendous decrease in Ki67 expression. 17β-estradiol and 
tamoxifen partially restored the expression of Ki67. 
 
5.4.4 Effect of PQ1 and tamoxifen on apoptotic proteins 
Programmed cell death, or apoptosis occurs either by activation of the death receptors or 
by a breach in the mitochondrial membrane integrity. Cytochrome C, a key player in induction of 
apoptosis cascade, is released from the inside of the mitochondria into the cytosol of the cell by 
the interaction of two important proteins involved in apoptosis, BAX and Bcl2. Upon apoptotic 
signals, proapoptotic protein, BAX gets activated while antiapoptotic proteins like Bcl2 prevent 
apoptosis by heterodimerization with BAX (Otter et al., 1998; Broker et al., 2005). Overall, the 
ratio of BAX and Bcl2 determines the integrity of the mitochondrial membrane.  In the present 
study, we conducted a time-dependent study by treating cells with PQ1 and tamoxifen in 
combination and alone for 1, 48 and 72 hr. We found a significant increase in BAX protein at 1 
hr in the presence of 500 nM PQ1 alone, tamoxifen alone and combination of PQ1 and 
tamoxifen (Figure 5.5A). We also observed a decrease in Bcl2 in the presence of tamoxifen 
alone and in combination of tamoxifen and PQ1 at 1 hr. At 48 hr, a significant decrease was seen 
in Bcl2 expression at 500 nM PQ1 and combination of tamoxifen and PQ1. Also, there was a 
significant increase in BAX in combinational treatment at 48 hr. Zhang et al. showed a decrease 
in Bcl2 but no effect on BAX in MCF-7 cells in the presence of 10 µM tamoxifen at 72 hr 
(Zhang et al., 1999). We found that at 72 hr, BAX and Bcl2 were significantly increased and 
decreased in the presence of tamoxifen and combination of tamoxifen and either PQ1 200 or 500 
nM, respectively. These results implicate that the combinational treatment not only significantly 
increases BAX but also decreases Bcl2. The ratio of Bcl2 and BAX is decreased significantly at 
1 hr in the presence of PQ1 alone and tamoxifen alone or in combination. Therefore, it indicates 
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that PQ1 has a rapid action on BAX activation. The effect on reduction of Bcl2 expression is 
relatively slow, staying constant at 48 hr before increasing again at 72 hr. 
A.                                                                                    B. 
 
 
Figure 5.5  Expression of proteins involved in apoptosis pathway- BAX, caspase 3, Bcl2 and 
survivin. 
A) Bcl2 and BAX levels were measured in cells were treated with 200 and 500 nM PQ1 and 
10µM tamoxifen and combination of tamoxifen with 200 or 500 nM PQ1 for 1, 48 and 72 hr. A 
significant increase in BAX was observed at all the treatments compared to control. Survivin 
measured for the same treatments at 1, 48 and 72 hr. A significant decrease in survivin was 
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observed in the presence of tamoxifen alone and in combination with both 200 and 500 nM PQ1 
at 48 hr. However, no effect on survivin was seen in the presence of 200 and 500 nM PQ1 alone. 
B) Caspase 3 expression was measured for the same treatments at 1, 48 and 72 hr. Histogram 
showing the changes observed in active caspase 3 at 1, 48 and 72 hr with different treatments. A 
2-fold increase was seen at 48 and 72 hr in the presence of combination of tamoxifen with 200 
and 500 nM PQ1. A histogram of three experiments with ± SD and statistical significance *p< 
0.05 for 48 hr and **p< 0.05 for 72 hr. Actin was used as a loading control for all the proteins. 
 
After BAX activation, a cascade of events driven primarily by the activation of 
proteolytic caspases results in the processing of intracellular structural proteins and regulatory 
enzymes that culminates in apoptotic cell death (Zhang A, 2004). Caspase 3 activation, an 
executioner caspase, is considered to be one of the last steps involved in the apoptosis cascade 
pathway (Mandlekar et al., 2000). Therefore, we examined the effect of combination of 
tamoxifen and PQ1 on caspase 3 activation. Interestingly, we did not find activation of caspase 3 
at 1 hr (Figure 5.5B). However, there was a significant increase in caspase 3 at 48 and 72 hr in 
the presence of PQ1 alone, tamoxifen alone and in combination of tamoxifen and PQ1 indicating 
caspase 3 activation takes time and stays at least through 72 hr. A 50% increase in active caspase 
3 was observed at 200 and 500 nM PQ1 at 72 hr. A 2-fold increase was observed in active 
caspase 3 both in the presence of combinational treatment of tamoxifen and 200 nM PQ1 and 
tamoxifen and 500 nM PQ1. This suggests that combination of both PQ1 and tamoxifen results 
in increased T47D cell death.  
In the present study, we also observed the effect of PQ1 and tamoxifen on the inhibition 
of apoptosis (IAP) protein, survivin (a group of proteins involved in inhibition of caspase 3, 7, 
and 9) (Altieri, 2003; Gazzaniga et al., 2003). Increase in expression of surviving is believed to 
protect cells against a possible default induction of apoptosis in the case of aberrant mitosis (Li et 
al., 1998). Many studies on clinical specimen have shown that survivin expression is invariably 
upregulated in human cancers and is associated with resistance to chemotherapy linked to poor 
prognosis, suggesting that surviving modulates the survival of cancer cells (Yamamoto et al., 
2008). Gazzaniga et al. found that survivin cannot be used as a prognostic factor for the relapse 
of superficial bladder cancer (Gazzaniga et al., 2003). However, in pre-clinical bladder tumor 
models, inhibition of survivin expression and/or function has been shown to impede tumor cell 
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proliferation, and markedly induce spontaneous or chemotherapy induced apoptosis (Margulis et 
al., 2008). We found no effect on survivin at 1 hr (Figure 5.5A); however, at 48 and 72 hr we 
found a tremendous decrease in survivin expression in the treatment of tamoxifen alone and 
combinational treatment of tamoxifen and PQ1 (200 or 500 nM). This suggests that tamoxifen 
decreases the survivin expression whereas PQ1 alone has no effect on survivin expression in 
T47D cells up to 72 hrs.  
We also observed survivin and BAX in T47D cells at 1, 48 and 72 hr by confocal 
microscopy. We found a nuclear localization of survivin and cytoplasmic as well as nuclear 
localization of BAX (Figure 5.6A, B). The confocal microscopy results showed the absence of 
survivin in tamoxifen treated cells at 48 and 72 hr. 
 
5.4.5 Measurement of Apoptosis by Nuclear Morphology and Flow Cytometry 
The effect of tamoxifen and PQ1 on the nuclear staining by using DAPI was measured. 
Apoptosis is characterized by morphologic changes such as shrinkage of the cell, condensation 
of chromatin, and disintegration of the cell into small fragments, apoptotic bodies (Kerr et al., 
1972). In the present study, we found more cells undergoing the process of apoptosis exhibited 
by blebbing, and fragmentation in the presence of PQ1 and tamoxifen alone and in combination 
(data not shown). APO-BrdU TUNEL assay kit was used to detect the DNA fragmentation of 
apoptotic cells. In apoptosis, DNA fragmentation exposes 3’-OH groups at which 
deoxynucleotidyl transferase (TdT) can add deoxyribonucleotides. 5-bromo-2’-deoxyuridine 5’-
triphosphate (BrdUTP) is an analog of deoxythymidine which gets incorporated at the 3’-OH 
group. We found an increase in the BrdUTP incorporation in the presence of PQ1 and tamoxifen 
alone and in combination at 48 and 72 hr (Figure 5.7). A 50% increase in apoptotic cells was 
observed at 48 and 72 hr in the presence of combinational treatment of tamoxifen and PQ1. 
There was no effect on the apoptosis in the presence of PQ1 or tamoxifen at 1 hr. Even though 
the apoptosis cascade starts in an hour shown by an increase in BAX and a decrease in Bcl2, it 
requires > 1 hr for the activation of caspases and DNA damage. 
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Figure 5.6  Confocal microscopy showing the expression of survivin and BAX proteins. 
A) Cells were treated with 200 and 500 nM PQ1 and 10 µM tamoxifen and combination of 
tamoxifen and either 200 or 500 nM PQ1 for 1, 48 and 72 hr. Tamoxifen treatment resulted in a 
decrease in survivin expression. Cells were stained with antirabbit Alexa fluor 568. B) Cells 
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were treated the same way as in (A); however; expression of BAX protein was observed using 
mouse secondary Alexa fluor 488 antibody. Cells were visualized by a confocal microscope 
(Carl Zeiss LSM 510 META). An increase in BAX was observed in the presence of tamoxifen.  
 
The results imply that the combination of PQ1 (200 and 500 nM) and tamoxifen (10 µM) 
results in an increase in apoptosis compared to the individual treatments. 
 
 
Figure 5.7  Flow cytometric analysis of apoptotic cells by APO-BrdU labeling. 
Cells were treated with 200 and 500 nM PQ1 and 10µM tamoxifen and combination of 
tamoxifen and 200 or 500 nM PQ1 for 48 and 72 hr. A 50% increase in apoptotic cell number 
was seen at both 48 and 72 hr in the presence of both tamoxifen and 200 nM or 500 nM PQ1. 
5.5 Conclusion 
Tamoxifen has been the drug of choice for the treatment of endocrine responsive breast 
tumors, but tamoxifen resistance has been an issue for very long time. We demonstrate for the 
first time that the combinational effect of PQ1, a gap junction activator, with tamoxifen has a 
potential use for treatment against breast cancer. We found a decrease in cell proliferation by 
MTT assay and significant decrease in the colony growth assay. We observed a significant 
increase in BAX, caspase 3 activation and DNA fragmentation in the presence of combinational 
treatment of PQ1 and tamoxifen as compared to their individual treatment. We also found that 
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survivin is significantly decreased in the presence of tamoxifen alone and combination of 
tamoxifen with either 200 or 500 nM PQ1. However, PQ1 alone does not affect survivin 
expression in T47D cells as observed at 1, 48 and 72 hr. The possibility of PQ1 affecting other 
caspases in inducing apoptosis has not been covered by the current study; therefore, we cannot 
rule out the involvement of other caspases. We propose that PQ1 might allow tamoxifen (MW= 
371.51) to pass through gap junctions between the cells, causing a rapid action of tamoxifen. In 
support of our data, Jensen and Glazer showed that forced expression of Cx43 in MCF-7 cells 
resulted in increased cell sensitivity to cisplatin at high density (Jensen and Glazer, 2004). Our 
work is based on the same concept as Jensen and Glazer demonstrating that the combinational 
therapy of tamoxifen and PQ1 shows more promising role in inducing apoptosis by caspase 3 
activation. But in our studies we did not overexpress the connexins, we used a gap junctional 
activator which can be easily administered with tamoxifen. However, more studies needs to be 
done to observe the combinational effect of PQ1 and tamoxifen in vivo. 
5.6 Significance  
Our study suggests that the combinational treatment may allow a decrease in tamoxifen 
concentration (lower than 10µM) in clinical use. This will have a strong implication that 
combinational treatment with gap junctional activators can lower the concentration of 
chemotherapeutic agent and thus may reduce side effect of these drugs. In future we would be 
conducting combinational studies of PQ1 and tamoxifen (dose reduced from µM to nM) and 
observe its effect on cell-based systems. Also, much of the work presented has focused in breast 
cancer cells; however, the role of gap junctional activators (PQ1) in drug sensitivity need not be 
limited to breast cancer. A variety of other cancers may take advantage of very similar 
mechanism and as a result other diseases may benefit from gap junction modulating pathway. 
 
Abbreviations: Substituted quinolines (code name PQ), Tamoxifen (TAM), MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)  
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Chapter 6 -  Hydronephrosis and Urine retention in Estrogen-
Implanted Athymic Nude Mice 
6.1 Abstract  
Subcutaneous estrogen pellet implantation is commonly practiced to induce tumor 
promotion in nude (Nu-FOXn1nu) mice for xenograft tumor modeling. Twelve out of twenty-
three, 18-week old nude mice, developed dysuria after estrogen pellet implantation. Physical 
examination revealed variably distended abdomen with palpable distended bladder. All mice 
were euthanized and necropsied. Blood samples of the mice were collected and serum estrogen 
concentration was measured. Necropsy revealed variable dilation of the urinary bladder and 
unilateral or bilateral dilations of ureters and kidneys. Microscopically, 12/23 mice and 13/23 
mice showed dilated urinary bladder and hydronephrosis, respectively. In conclusion, 
hydronephrosis and urine retention were observed in estrogen-implanted nude mice. 
 
6.2 Background  
Estrogens have been associated with tumor development in many experimental animals 
and humans. Estrogen acts as a tumor promoter in rat liver carcinogenesis (Shirai et al., 1987), 
spontaneous human endometrial and mammary carcinomas (Nenci et al., 1988). Therefore, 
estrogen pellets are frequently used as a tumor promoter in animal models of human neoplasia. 
Besides being a tumor promoter, estrogen has been shown to increase urethral tone in mice 
(Game et al., 2008). 
Urogenital infections have been shown to flare up in elderly women. In post-menopausal 
women, estrogen therapy reduces vaginal atrophy (Rozenberg et al., 2004), which normalizes 
vaginal flora thereby effective in reducing urinary tract infections (Robinson and Cardozo, 
2003).  On the contrary, hydronephrotic effect of high dose estrogen was observed in DDD 
(deutsche Maus at Denken) strain male mice (Mannen et al., 1993). In another study conducted 
by Buhl et al., estrogen-treated adult male CF1 (Carworth Farms 1) mice showed an increase in 
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urine volume. In both male and female gonadectomized DS (mutation disorganization) strain 
mice exposed to 17β-estradiol, significant urine retention and 100% hydronephrosis were 
observed (Kuroda et al., 1985). An additional study found that 17β-estradiol treatment 
administered via subcutaneous pellets caused hydronephrosis and urine retention in female 
C57BL/6J mice (Levin-Allerhand et al., 2003). The results observed in lab animals seem to be 
contradictory to the studies conducted in humans. It could be due to different dose regimen of 
estrogen in lab animals and also post-menopausal women are deprived of estrogen for a very 
long time which could trigger many pathways. 
Estrogen implantation is commonly practiced to promote tumor growth in nude (Nu-
FOXn1nu) mice. After 1 week of estrogen implantation, 1x107 T47D human breast cancer cells 
were injected at the right inguinal region. Multiple mice developed dermatitis and/or bloated 
abdomens after four weeks of estrogen implantation. The tumor growth study was terminated 
and mice received supportive care prior to euthanasia. 
This case report describes similar clinical and pathologic conditions in estrogen-
implanted nude mice as observed in the above mice studies; however, it reports for the first time 
that estrogen implantation is linked to urine retention and hydronephrosis in nude mice. 
 
6.3 History, Gross findings and laboratory results  
Twenty-five 4 week old female Nu-FOXn1nu were obtained from Charles River 
Laboratories (Wilmington, MA, USA). A 1.7 mg 17β-estradiol pellet (Innovative Research of 
America, Sarasota, Florida), was subcutaneously implanted with a trochar in the subscapular 
region at 43 days of age. No inflammation/redness around the implantation area was observed 
after 2-3 days. Three weeks after estrogen implantation, pruritus and ulcerative dermatitis were 
observed in the perineum in some mice. The lesions then spread to the hindlegs, over the dorsum 
of the tail head, and in one mouse to the forelegs. After 4 weeks of estrogen implantation, mice 
looked bloated but otherwise healthy. On physical examination, in living mice, the urinary 
bladder appeared distended and was easily palpable.  
The mice were euthanized by CO2 asphyxiation and necropsy was performed. Necropsy 
revealed a variably enlarged urinary bladder filled with clear yellow urine, mild to moderate 
hydroureter and unilateral or bilateral hydronephrosis (Figure 6.1). The majority of the mice had 
121 
 
variable dilation of the uterus. After euthanasia, blood was collected via cardiocentesis from 14 
mice and tested for serum estrogen level (A.3, Figure S13). In the rest of the mice, blood was not 
collected. 2/14 mice had no estrogen pellet, and were found to be healthy (Figure 6.2) having 
normal (3-9 pg/ml) serum estrogen level. 6/14 mice had increased estrogen level (36-260 pg/ml). 
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Figure 6.1  Urogenital tract of an affected nude mouse.   
Bilateral hydronephrosis and enlarged bladder filled with urine in a nude mouse. 
Figure 6.2  Urogenital tract of an unaffected nude mouse.   
Grossly, kidneys and bladder look normal. 
Figure 6.3  HE stain of kidney of an affected nude mouse.   
There is a dilation of the renal pelvis. The ureter is moderately dilated. Note: flattened renal papillae. 
Figure 6.4  HE stain of the urinary bladder. 
The urinary bladder is dilated with flattened mucosal epithelium and muscular layers. The lumen is free of inflammatory cells or 
hemorrhage. The inset reveals multifocal infiltrates with low to moderate numbers of plasma cells within the muscular layer. 
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6.4 Differential Diagnosis  
Differential diagnosis for hydronephrosis in animals includes anything that obstructs the 
urinary tract at the level of the urethra, urinary bladder or ureters. Urinary calculi and severe 
cystitis are two of the common causes of urinary tract obstruction in domestic animals. Masses in 
the caudal abdomen or pelvis such as abscesses may cause external pressure to the urinary tract 
and cause a functional obstruction. In addition, displacement of the bladder through perineal 
hernias and acquired urethral or ureteral strictures can block the flow of urine.  
 Perineal ulcerative dermatitis preceded the clinical signs, therefore, an acquired stricture 
due to scarring around the perineum as sequelae to dermatitis or a blockage due to cystitis could 
not be ruled out with initial clinical presentation. There was no evidence of blockage due to 
scarring, cystitis, urinary calculi or pressure from adjacent masses in any of the mice. Therefore, 
the most likely cause for the clinical findings was urine retention associated with estrogen 
administration. 
 
6.5 Microscopic Findings  
Microscopically, the distended urinary bladders had flattened epithelium and decreased 
thickness of the muscular layer (Figure 6.4). All mice (12) that had distended abdomens had 
microscopically variable degrees of dilation of the urinary bladder, unilateral or bilateral dilation 
of the kidneys, and mild to moderate hydroureters. Six of the histologically affected mice had 
multifocal infiltrates with low to moderate numbers of plasma cells within the tunica muscularis 
(Figure 6.4, inset). There was no evidence of hemorrhage or inflammatory cells within the 
bladder lumen in any of the mice examined. The mice with ulcerative dermatitis of the perineum 
had no histologic evidence of bacterial infection, however lesions were not cultured.  
Microscopically, 10/23 mice having gross lesions of kidneys showed hydronephrosis. In 
addition, three mice with no gross lesions had similar histologic lesions. Five histologically 
affected mice that had hydronephrosis also had unilateral mild to marked dilation of the renal 
pelvis with flattening of the renal papillae (Figure 6.3). The remaining (eight) mice had mild to 
marked bilateral renal pelvis dilation. The proximal ureters were moderately to markedly dilated 
in all mice that had histologic evidence of hydronephrosis.  
125 
 
Two mice had unilateral suppurative nephritis. One of these had multifocal infiltration of 
large numbers of neutrophils within the tubules. The other mouse had multifocal randomly 
distributed infiltrates of neutrophils within the cortex and medulla with intralesional colonies of 
Gram-positive cocci, which was confirmed by Gram’s stain. 
 
6.6 Discussion  
The current report demonstrates that the subcutaneous implantation of 1.7 mg 17β-
estradiol pellet resulted in severe urine retention in the bladder with uni- or bi-lateral 
hydronephrosis in Nu-FOXn1nu. Hydronephrosis is distention of the kidney with urine, caused by 
the increased pressure in the renal pelvis when the flow of urine is obstructed. It can be due to 
any type of urinary obstruction that occurs at any level of the urinary tract, from the urethra to 
the renal pelvis. This obstruction may be complete or partial and can be acquired, inherited or 
congenital. Certain inbred strains of mice, such as the C3H, C57L, and DDD mice, have been 
described to have an higher incidence of hydronephrosis, which are presumed to be inherited 
(HH, 1988). An autosomal recessive, progressive hydronephrosis has also been described in 
C57BL/6J mice (Horton et al., 1988). Also, various transgenic mouse strains develop 
hydronephrosis due to their genetic alterations.  In our study, we could not determine the cause 
of urine retention. However, bacterial infection was not evident in all histological examinations 
of kidney and bladder except in one kidney of a mouse which had intralesional colonies of 
Gram-positive cocci. Struvite uroliathiasis in estrogen-treated ovariectomized female nude mice 
with Staphylococcus intermedius-induced cystitis was observed (Gibbs et al., 2007). However, 
in our study we did not observe any significant bacterial infection which could have been 
associated with urine retention. Ascending infections of the urinary tract was documented in 
female nude mice housed on nonautoclaved corncob bedding and implanted with 0.36 mg 
estrogen pellets for 9 wk (Simpson JE, 2002). In the present study, there was no effect on 
changing the corn cob bedding to autoclaved paper bedding. The initial study was to generate 
tumor growth in Nu-FOXn1nu; however, due to the adverse side effects of estrogen implantation, 
the study had to be terminated for the physical well being of the mice. 
In all, twenty-three mice were assessed grossly or microscopically for urine retention and 
hydronephrosis. Two mice were not assessed due to untimely death. In 14/23 mice, blood was 
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collected and serum estrogen level was measured. Normal serum estrogen level is 2-5 pg/ml in 
mice. 2/14 mice had no estrogen pellet, and were found to have normal serum estrogen level (3-9 
pg/ml) and healthy until euthanasia with no gross or microscopic lesions in the kidney or bladder 
(Figure 6.2). This suggests that estrogen implantation might have caused the urogenital effects 
observed in estrogen-implanted nude mice. 6/14 mice had increased estrogen level (36-260 
pg/ml) and increased bladder volume either grossly or microscopically (Figure 6.5) and 4 mice 
also had hydronephrosis. 
 
                                   
 
Figure 6.5  Pie chart showing hydronephrosis, urine retention in mice in which estrogen 
level was measured.   
Urine retention was seen in 6 mice, out of which 4 also exhibited hydronephrosis.  Six mice were 
unaffected but high serum estrogen level was observed. Two control animals with normal 
estrogen level were also found unaffected. Blood serum from 14 mice was sent for the estrogen 
level measurement. The parenthesis depicts the number of mice in each group followed by the 
serum estrogen levels.  The unit for the serum estrogen levels is pg/ml. Total mice in the group = 
14. 
 
Out of these 6 mice, only one had 36 pg/ml; whereas, others had 123-260 pg/ml serum 
estrogen levels. None of the mice with elevated estrogen levels developed hydronephrosis alone 
without urine retention in the bladder. This suggests that urine retention preceded 
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hydronephrosis. 6/14 mice were unaffected with high estrogen level ranging from 43-220 pg/ml, 
however, only one animal had 220 pg/ml whereas others had 43-102 pg/ml serum estrogen 
levels. A table showing the estrogen levels in each mouse is provided in Appendix A.3 (Table 
S12). It should be noted that the estrogen pellet was a 60-day release pellet. According to the 
manufacturer, estrogen levels should not be high after 60 days. But the estrogen levels were 
found high in the serum even after 105 days of the estrogen implantation. Out of total 23 mice, 
12 were grossly found to have increased urine retention and 10 were grossly found to have either 
uni- or bi-lateral hydronephrosis (Figure 6.6). Microscopically, 12/23 and 13/23 mice showed 
dilated bladder and hydronephrosis, respectively. In some mice, hydronephrosis was observed on 
microscopic examination.  
 
  
 
Figure 6.6  Pie chart showing hydronephrosis and urine retention in all 23 mice.   
The pie chart is based on the gross examination. Urine retention was observed in 12 mice, out of 
which 10 mice also showed hydronephrosis. Eleven mice were unaffected and were healthy. The 
parenthesis depict the number of mice in each group. Total mice in the group = 23. 
 
In conclusion, estrogen implantation can cause urine retention with uni- or bi-lateral 
hydronephrosis in nude mice. Further studies need to be done to fully understand the relationship 
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of estrogen implantation to urine retention. An effective safer dose regimen of estrogen needs to 
be established in nude mice. 
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Chapter 7 -  General Discussion  
In all normal cells, DNA repair mechanisms to some extent can repair the DNA damage 
caused by carcinogens. If the damage is substantial, it overpowers the cell’s repair mechanism 
capability leading to tumor growth. Therefore, an initiator along with one or multiple promoters 
facilitates the tumor progression. Promoters, for example, phorbol esters have been shown to 
exert many cellular effects including cell membrane changes, alteration of growth factor 
responses and even mutations. Interestingly, an initiated cell despite having mutations in growth 
regulatory genes still require promoters to cause tumor formation indicating that cellular controls 
are vital in the body. Therefore, during the cascade of phenotypic changes occurring at the 
promoter stage, alteration in cellular controls might be rendering an initiated cell towards 
forming a tumor. Cell-cell (intercellular) and cell-matrix interactions are the key players in 
achieving cellular control. Considerable evidence suggests that the inhibition of cell-cell 
communication is one of the critical actions performed by promoters. The inhibition or blockage 
of transmission between the cells could allow proliferation and emergence of neoplastic cells. 
A positive correlation has been found between the restoration of cell-cell communication 
and decrease in cell proliferation and growth. This suggests that intercellular communication 
could be transmitting regulatory molecules from one cell to another. Despite having considerable 
evidence that cell-cell communication affects cell growth, specific growth regulatory molecules 
passing through gap junction channels have not been established yet. However, small molecules 
such as ATP, AMP, ADP, Ca2+, inositol triphosphate, and glucose have been shown to pass 
through gap junctions. The scientific evidence showing decrease in gap junctions and cell-cell 
communication in tumor cells and tissues led to restoration studies of gap junctions in vitro and 
in vivo. So far, studies include transfection of connexin genes in many tumor cell lines and 
rodent studies. These approaches are informative; however, not feasible to apply in a clinical 
setting. Currently very few compounds have shown to increase gap junctional activity such as 
retinoids, lycopene and carotenoids. Thus, there is a great need of gap junctional activators 
which can open up the gap junction channels and increase cell-cell communication. In my study, 
I found PQ1, a novel gap junctional activator which also decreases tumor growth. 
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In the current study, I first examined the gap junctional intercellular communication 
(GJIC) in breast cancer. Breast cancer is the second leading cause of cancer deaths in North 
American women. The risk of developing breast cancer in a lifetime of women is one in seven. 
Breast cancer is caused by many factors: some of them are like hereditary, age, diet, lifestyle, 
and environment. Hereditary constitutes only about 5-10% of the total breast cancer cases. 
Therefore, other factors play a critical role in the formation of breast cancer. The effect of 2, 3, 7, 
8-tetrachlorodibenzo-p-dioxin (TCDD) on the GJIC in breast cancer cells and normal mammary 
epithelial cells (HMEC) was observed. HMEC exhibit extensive GJIC and the most predominant 
Cx present in HMEC is Cx43. A significant amount of Cx43 in HMEC compared to different 
human breast cancer cells- MCF-7, T47D, ZR-75, MDA-MB-231 and MDA-MB-453 cells was 
found. Phosphorylation of Cx proteins have been shown to decrease the GJIC. Interestingly, I 
found an increase in the phosphorylated form of Cx43 in MCF-7 cells while only one 
unphosphorylated form of Cx43 was seen in the whole cell extract of HMEC.  
MCF-7 cells were chosen to conduct the experiments with TCDD because MCF-7 is a 
well-established human breast cancer cell line used as a representative of breast cancer. GJIC can 
be measured by using scrape load/dye transfer (SL/DT) assay. Lucifer yellow is a dye which 
passes through gap junctions; therefore, more the transfer of the green dye from the line of cut, 
the more is the GJIC. HMEC showed a significant increase in the dye transfer compared to 
MCF-7 cells. In the presence of 10 and 100 nM TCDD, lucifer yellow dye transfer in MCF-7 
cells was decreased while 200 nM caused a tremendous decrease in dye transfer in HMEC. 
Confocal microscopy showed a decrease in Cx43 plaque formation in MCF-7 cells in the 
presence of TCDD. Interestingly, confocal microscopy showed a redistribution of Cx43 plaques 
in HMEC from the membrane to the perinuclear region in the presence of TCDD, also confirmed 
by protein measurement of nuclear and cytoplasmic extract of Cx43. In the presence of TCDD, 
MCF-7 cells showed an increase in the phosphorylated form of Cx43. Many kinases are involved 
in the phosphorylation of Cx43 proteins. Expression of different classical forms of PKC- α, β, 
and, γ was observed but no effect of TCDD on PKC β and γ was observed. However, an increase 
and activation in PKC α in the presence of TCDD in MCF-7 cells was seen. Further, 
immunoprecipitation studies showed a strong interaction between phosphorylated form of Cx43 
and PKC α. Calphostin C, an inhibitor of PKC showed to ameliorate the TCDD caused effects on 
GJIC in a dose-dependent manner.  
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Restoration of gap junctions has been shown to decrease tumor growth both in vitro and 
in vivo. In the present study, we collaborated with Dr. Duy H. Hua, a distinguished chemist at 
Kansas State University. Dr. Hua’s lab synthesized a new class of substituted quinolines (PQs). 
A computational docking study showed that PQs has a relatively high binding to gap junction 
protein, Cx43. Thus, PQs were used in this study to find their effect on human breast cancer 
cells. Screening of PQ1-PQ5 was performed at different doses to observe their effect on GJIC by 
flow cytometry in different human breast cancer cell lines. The data suggested that compound 
PQ1 (200 and 500 nM) is a strong candidate to increase GJIC in T47D cells. Furthermore, 
SL/DT and colony growth assay were performed to measure GJIC and determine the effect of 
the PQ1 on the colony formation in HMEC and breast cancer cells, respectively. The results 
showed that PQ1 have a significant antitumor effect in human breast cancer cells compared to 
control without treatment or HMEC. 200 nM PQ1 showed a 30% increase in the GJIC in T47D 
cells; however, there was no effect of PQ1 treatment on GJIC in HMEC. In addition to an 
increase in GJIC, 80-95% growth attenuation was observed by PQ1 in colony growth assay. 
Since an increase in GJIC has been shown to increase cell death, I investigated the effect of PQ1 
on active caspase 3. Indeed, a significant increase in caspase 3 in the presence of PQ1 was seen. 
The in vitro effect was simulated in vivo in nude mice. The PQ1-treated animals showed a 
significant decrease in xenograft tumor growth of T47D cells in nu/nu mice compared to control 
or tamoxifen-treated animals. The results showed that PQ1 compound have a promising role in 
exerting antitumor activity in human breast cancer cells.  
Combinational effect of PQ1 and tamoxifen was tested in T47D human breast cancer cell 
line. The outcome of my previous work led to a hypothesis that PQ1, a novel gap junctional 
activator, might reduce the side effects of tamoxifen by potentiating apoptotic signal and 
increasing cell communication in breast cancer cells.  
A significant increase in BAX expression, caspase 3 activation and DNA fragmentation 
in combinational treatment of tamoxifen and PQ1 as compared to their individual treatments was 
observed. Tamoxifen alone and combination with PQ1 showed a decrease in the survivin 
expression while PQ1 alone shows to be independent of survivin-mediated pathway. The 
combinational treatment of tamoxifen and PQ1 showed a significant decrease in cell viability 
compared to tamoxifen treatment alone.   
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Besides the three objectives, an interesting observation was made while conducting 
experiments on nude mice. Nude mice were implanted with 17β-estradiol in the subscapular 
region. After a month of implantation, bloating in some of the animals was seen. At euthanasia, 
in one of the mice we detected hydronephrosis and urine retention. Further investigation was 
conducted to establish the source of the enlarged kidneys and bladder by measuring plasma 
estrogen levels in the nude mice. I reported that 17β-estradiol might be the initiating factor for 
hydronephrosis and urine retention in nude mice. This was the first study to relate estrogen with 
hydronephrosis and urine retention in nude mice. 
Overall, I have established that an environmental pollutant, TCDD decreases gap 
junctional intercellular communication (GJIC) in breast cancer cells and also affects GJIC in 
normal mammary epithelial cells. Further, I found a gap junctional activator, PQ1 and tested its 
efficacy in breast cancer cells and nude mice. The results obtained in PQ1 study supported the 
hypothesis that restoration of gap junctions decreases tumor cell growth. In addition, I found an 
increase in active caspase 3 suggesting the induction of apoptosis. Currently, tamoxifen is a drug 
of choice for endocrine-responsive breast cancer patients. Patients over time have been shown to 
develop resistance to tamoxifen. Also, tamoxifen has many side effects, including the risk of 
endometrial cancer. Tamoxifen is an antiestrogen shown to inhibit estrogen-mediated 
upregulation of various gene products and induces apoptosis. Therefore, if we combine 
tamoxifen and PQ1, does it increase the cell death leading to increased apoptosis? The present 
study demonstrates for the first time that combinational treatment of tamoxifen and PQ1 (gap 
junctional activator) can be used to potentiate apoptosis of T47D human breast cancer cells. This 
could either lead to a decrease in the dose or decrease the length of time patients are given 
tamoxifen, thereby, might reduce the side effects caused by tamoxifen. 
Therefore, my dissertation has provided information that GJIC plays an important role in 
breast carcinogenesis.  
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Appendix A - Supplemental data  
 
A.1.  Supplemental Data for Chapter 3 
 
 
 
 
Figure S 1  Effect of TCDD on PKC isoforms.  
The figure shows no significant effect of TCDD on PKC β and γ in MCF-7 cells.  
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A.2.  Supplemental data for Chapter 4 
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Figure S 2  Effect of PQ1-PQ5 on GJIC in MDA-453 human breast cancer cells. 
Materials and Methods for parachute assay: Seed the cells in a six-well plate on the first day. 
Simultaneously, seed another population of same type of cells in a 25 cm2 flask. Allow the cells 
in the six-well plate to reach 85% confluency. Add 4 µl of vibrant-DiD stain in 1 ml DMEM F-
12 media in a conical tube. Add the prepared media into each well for 20 min. After 20 min, 
aspirate out the media and rinse the cells 3X in DMEM F-12 media. Incubate the cells in the 
media overnight at 37°C. Next day, add 2 µl of calcein-AM (acetoxy-methyl ester) in 1 ml of 
DMEM-F12 in 25 cm2 flasks containing the same type of cells as in the six-well plates. Incubate 
for 30 min at 37°C. Rinse the flasks 3X with PBS. After rinsing, trypsinize the cells and 
centrifuge at 2,000 rpm for 5 min. Resuspend the cells in DMEM F-12 and add on the top of 
cells labeled with vibrant DiD (recipient cells) in six-well plate. Dose the cells with appropriate 
PQ compound and allow the cells labeled with calcein-AM (donor cells) to adhere onto the 
recipient cells. After 2 hr, trypsinize the cells and after centrifugation rinse the cells in PBS. 
Aspirate the media and resuspend the cells in PBS at the last wash. Prepare control cells: 
unstained, calcein-labeled, vybrant DiD-labeled cells and both calcein-AM and vybrant DiD 
labeled cells. Measure the cells by flow cytometry. Calcein-AM is measured at 488 nm and 
vibrant DiD at 568 nm. 
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Figure S 3  Effect of PQ1-PQ5 on GJIC in MCF-7 cells.  
Parachute assay was performed as described in Figure S2. We did not see any increase in GJIC in MCF-7 cells with compounds PQ1-
PQ5. 
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Figure S 4  Effect of PQ1-PQ on GJIC in ZR75 cells. 
Parachute assay was performed as described in Figure S2. There was no significant increase found in GJIC in ZR75 cells in the 
presence of PQ1-PQ5. 
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Figure S 5  Effect of PQ1-PQ5 on GJIC in MDA 231 cells. 
Parachute assay was performed as described in Figure S2. The graph shows no significant increase in GJIC in MDA 231 cells. 
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A. 
 
 
B. 
        
 
Figure S 6  Effect of PQ1 on GJIC in T47D cells.  
A) T47D cells were incubated with PQ1 and gap junctional activity was measured by flow 
cytometry. Succinic acid (SA) was used as a control. We found a 35-40% increase in GJIC by 
parachute assay. B) Histogram showing a significant increase in GJIC by PQ1 in T47D cells by 
parachute assay. 
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Figure S 7  Chart showing effect of PQ1-PQ5 in different human breast cancer cell lines. 
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A.                                                     B. 
 
Figure S 8  Xenograft tumor formation in nude mice. 
The picture depicts the formation of xenograft T47D tumors in the inguinal region of nude mice. 
A) Shows the tumor formation in a control nude mouse B) Shows the tumor formation in a PQ-
treated nude mouse. 
 
 
 
Figure S 9  Xenograft Tumor Growth of T47D Cells in Nu/Nu Mice.   
Mice were implanted with 17 β-estradiol pellets (1.7 mg/pellet) subcutaneously into the inguinal 
region before the injection of 1 x 107 T47D cells. Animals received treatment at 1 µM PQ1 or 10 
µM tamoxifen. The results after 6 days of injection show a decrease in tumor growth of PQ1-
treated animals compared to control or tamoxifen.   
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Figure S 10  Effect of PQ1 on Ki67 expression in Xenograft T47D tumor formation in nude 
mice. 
Tumors were harvested from the inguinal region of nude mice after euthanasia at the end of the 
study. Harvested tumors were fixed in 10% neutral buffered formalin for minimum 24 hr. After 
fixation, immunohistochemistry (IHC) was performed. We did not find any difference in Ki67 
expression in control versus PQ1-treated tumor tissues harvested from nude mice. This could be 
due to increased tumor growth. The tumor size became so huge before the first injection of PQ1 
(1 µM). We believe that the increased tumor size in the beginning did not allow PQ1 to either 
reach effectively to all the cells or the dose of PQ1 was not sufficient enough for such a big size 
tumor. Ear notching was performed to distinguish between the animals. R= Right notch, L= Left 
notch, N= No notch. The numbering denotes the cage number. A denotes the tumor, as I was 
interested in collecting brain also; therefore, I used A= tumor, B= brain. Three mice were housed 
per cage. R1A, R2A, L2A= tamoxifen-treated animals. L1A, R3A, N3A= PQ1-treated animals. 
N1A, L3A, R4A, L4A= control animals. L4A was euthanized at an early stage of the study 
because of humane reasons.  N2A, N4A did not show any tumor formation. Tamoxifen (1 µM) 
was used as a positive control for tumor attenuation. Materials and Methods for IHC: 
Formalin fixed tumor tissue was cut into 5 µ size before paraffin-embedding them onto the 
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slides. Slides were baked for 25 min at 55°C. Slides were put in the xylene wash three times for 
5 min each followed by graded alcohol baths- in 100% ethanol 2 times for 5 min each, 95% 
ethanol one time for 5 min, 80% ethanol one time for 5 min, distilled water for 5 min. Slides 
were pretreated with sodium citrate, pH 6.0 for the antigen retrieval method in a steamer for 20 
min followed by cooling of the slides for 15 min. Blocking was done for one hr in 3% BSA in 
PBS at room temperature. Slides were incubated with Ki67 antibody (Santa Cruz, CA) for two hr 
at room temperature. Slides were washed in 0.1% PBS/T for 15 min. Secondary biotin labeled 
anti-rabbit antibody (1:200) was used for 15 min at room temperature. Slides were again washed 
in 0.1% PBS/T for 15 min. ABC elite enzyme reagent (Vector Lab) was applied for 15 min at 
room temperature. Slides were washed for 15 min in 0.1% PBST. Slides were immersed in 
distilled water for 5 min prior to the addition of substrate-chromogen (3, 3 diaminobenzidine- 
DAB). Slides were observed under the microscope and when color development was observed, 
slides were immediately transferred to distilled water for 5 min. Counter-staining was done with 
hematoxylin. Slides were rehydrated again in xylene and ethanol before mounting them with the 
mounting media. 
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Figure S 11  Effect of PQ1 on Cx43 in xenograft T47D tumors harvested from nude mice. 
We did not find any significant differences in the expression of Cx43 in the control versus PQ1-
treated nude mice. Ear notching was performed to distinguish between the animals. R= Right 
notch, L= Left notch, N= No notch. The numbering denotes the cage number. A denotes the 
tumor, as I was interested in collecting brain also; therefore, I used A= tumor, B= brain. Three 
mice were housed per cage. R1A, R2A, L2A= tamoxifen-treated animals. L1A, R3A, N3A= 
PQ1-treated animals. N1A, L3A, R4A, L4A= control animals. L4A was euthanized at an early 
stage of the study because of humane reasons.  N2A, N4A did not show any tumor formation. 
Tamoxifen (1 µM) was used as a positive control for tumor attenuation. Materials and Methods 
for confocal microscopy: Formalin fixed human breast tissue was cut into 5 µm size before 
paraffin-embedding them onto the slides. Slides were baked for 25 min at 55°C. Slides were put 
in the xylene wash three times for 5 min each followed by graded alcohol baths- in 100% ethanol 
2 times for 5 min each, 95% ethanol one time for 5 min, 80% ethanol one time for 5 min, 
distilled water for 5 min. Slides were pretreated with sodium citrate, ph 6.0 for the antigen 
retrieval method in a steamer for 20 min followed by cooling of the slides for 15 min. Blocking 
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was done for one hour in 3% BSA in PBS at room temperature. Slides were incubated with anti-
mouse Cx43 (1:300) overnight at 4°C. After washing three times in PBS, slides were incubated 
with Alexa Fluor 568 nm for 3 hr at 4°C. Slides were stained with DAPI (nuclear stain) for 1 min 
and washed 3X with PBS. Slides were coversliped and observed under confocal microscope 
(Carl Zeiss LSM 510 META, Narashige, MN). 
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Figure S 12  Effect of PQ1 on gap junctions observed by Electron Microscopy. 
T47D cells were dosed with PQ1 for 1 hr and ultrastructural study was performed to examine the 
effect of PQ1 on gap junctions. We found an increase in number of gap junctions in PQ1-treated 
cells compared to control cells. Materials and Methods for Electron microscopy: T47D cells 
were grown in a monlolayer in a trans-well plate, incubated with 10, 100, 200, and 500 nM PQ1. 
Cells were fixed in Karnosvsky’s-cacodylate fixative (a 50/50 solution of 2.0% 
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paraformaldehyde and 2.5% gluteraldehyde in 0.1M cacodylate buffer) at 4°C for approximately 
2 hr. Fixative was replaced with fresh cold modified Karnosvsky’s-cacodylate fixative, for 
approximately 2 hr. The cells were rinsed three times in chilled 0.1M cacodylate buffer and post-
fixed in cold 1% osmium tetroxide-0.1Mcacodylate buffered fixative solution for 30 and 60 min, 
respectively. After three 5 min washes in cold doubled distilled water, the samples were then 
dehydrated in a series of increasing strength ethyl alcohol solutions (50%, 70%/ uranyl-acetate, 
70%, 70%, 95%, 100%, 100%). The cells were stained for 60 min with uranyl acetate added to 
the first 70% alcohol solution. Dehydration was completed with two 20-minute rinses in 100% 
acetone. The specimens were then infiltrated with three increasing concentrations of resin in 
acetone ending in 100% resin for periods of 2-12, 2-12, 8-12 hours respectively. All samples 
were then embedded in Epon LX112 embedding medium then polymerized at 45°C for 24 hr 
then 60°C for another 24 hr. Embedded tissues were trimmed and sectioned on an Ultracut E-
Reichert-Jung ultramicrotome (C. Reichert Optische Werke AG, 219, A-1171 Wien, Austria). 
Thick sections (0.5 microns) were cut initially from blocks, stained with Toluidine Blue, and 
examined with light microscopy. Silver and gold thin sections (approx 90 nm thickness) were 
taken from each specimen, retrieved to copper grids, allowed to dry, and then stained with uranyl 
acetate and lead citrate. The sections were then examined and viewed with a Hitachi H-300 
electron microscope utilizing Kodak 4489 electron microscope film. Standard dark room 
procedures were used to print all micrograph film.  
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A.3.  Supplemental data for Chapter 6 
 
Animal 
Number
Estrogen 
level 
(pg/ml)
                          Gross findings              Microscopic findings
C1-RLN 173 Bladder  and uterus distended Marked bladder, one kidney ok, other with dilated 
ureter
C1-RTN 220 OK, only uterus distended Ok
C1-LLN 123 Bladder ok, uterus distended Ok
C1-LTN Bladder and uterus distended, 
kidneys distended 
moderate to marked hydronephrosis X2
C1-NN Uterus distended, kidneys looked 
normal
1 ok other marked dilate ureter and mild pelvis- 
kidney, moderate with m/f plasma cell  infiltrate
C2-RLN 91 Bladder ok, uterus distended Ok, mild dilation of bladder
C2-RTN 36 Hydronephrosis, uterus and 
bladder moderately distended 
mod X2 , mild with plasma cells
C2-LTN Big Kidney, bladder and uterus 
distended
C2-LLN Bladder was normal, Kidneys 
looked normal
1 is mild, other OK- kidney, bladder mod with plasma 
cell in muscle
C2-NN Severe hydronephrosis seen, 
bladder and uterus distended
Unilateral hydronephrosis, 3 m/f suppurative 
nephritis
C3-RLN Kidneys hydronephrosed, bladder 
distended
3 kdneys, PM change and moderate hydronephrosis 
of 1
C3-RTN Animal was grossly bloated 
bladder was enlarged, uterus 
highly distended
Mild-mod kidney, bladder dilated w mucin
C3-NN 161 everything ok, uterus distended OK, mild dilation of bladder
C3-LLN 0 no pellet seen, uterus was swollen Normal, no bladder
C3-LTN 102 everything normal,  uterus 
distended
Ok
C4-NN 260 lesions around anus, kidneys 
normal
Bladder moderately dilated
C4-RTN 202 Kidneys enlarged,  bladder 
distended
1 marked enalarged other OK- kidney, mod. Bladder 
w plasma cell in muscle
C4-RLTN 43 pellet was little out,  kidneys were 
normal, uterus distended
Both kidneys mod. dilated, bladder ok
C4-LLN Left kidney hydronephrosed, 
uterus and bladder distended
Kidneys -1 mod. dilated, other supp nephritis w
bacteria
C4-LTN Animal died, no sample taken
C5-NN 9 no pellet seen, uterus normal Ok 
C5-RLN 222 Hydronephrosis, Uterus and 
bladder distended
1 moderate other enlarged ureter, marked bladder
C5-LLN 427 submandibular growth  was seen 
on left side
Ok
C5-RTN Kidneys highly enlarged, uterus 
and   bladder distended
Marked hydronephrosis with hem. and infarct
C5-LTN Kidneys hydronephrosed, uterus 
and bladder distended
Marked X2, bladder marked 
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Table S13  Gross and microscopic findings in individual mice associated with 
hydronephrosis and urine retention. 
Mice were housed five per cage. Ear notching was performed to distinguish between the animals. 
C5= Cage and number of the cage. RTN= Right top notch, LTN= Left top notch, RLN= Right 
low notch, LLN= Left low notch, NN= No notch, Hem= haemorrhage, Mod= moderate, PM= 
post-mortem. Gross findings were observed at the time of euthanasia and were mostly described 
based on the appearance of kidney and bladder. Cardiocentesis was performed immediately after 
animal was euthanized. Estrogen levels were measured in pg/ml. Microscopic findings were 
investigated by a pathologist.  
 
 
 
                        
 
Figure S 14  Cardiocentesis in a nude mouse. 
In mice, cardiocentesis should be performed immediately within 1 min after euthanasia. 
 
